ParkerVision (PRKR) 10-K 14 Apr 20 2019 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 30, 2020	Jun. 28, 2019
Document And Entity Information [Abstract]
Document Type	10-K
Document Period End Date	Dec. 31, 2019
Amendment Flag	false
Entity Registrant Name	PARKERVISION INC
Entity Central Index Key	0000914139
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Well-known Seasoned Issuer	No
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Public Float			$ 3,069,058
Entity Common Stock, Shares Outstanding		43,102,745

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
CURRENT ASSETS:
Cash and cash equivalents	$ 57	$ 1,527
Accounts receivable, net		2
Finished goods inventories, net		98
Prepaid expenses	505	538
Other current assets	117	55
Held for sale assets		65
Total current assets	679	2,285
Property and equipment, net	70	129
Intangible assets, net	2,878	3,902
Operating lease right of use assets	283
Other assets, net	16	15
Total assets	3,926	6,331
CURRENT LIABILITIES:
Accounts payable	2,328	655
Accrued expenses:
Salaries and wages	78	122
Professional fees	499	379
Statutory court costs	369	114
Other accrued expenses	1,081	563
Related party note payable, current portion	86	37
Secured note payable, current portion	1,222	2,400
Unsecured notes payable	225
Operating lease liabilities, current portion	250	86
Total current liabilities	6,138	4,356
LONG-TERM LIABILITES:
Secured contingent payment obligation	26,651	25,557
Convertible notes, net	2,733	837
Related party note payable, net of current portion	793	799
Operating lease liabilities, net of current portion	305	91
Other long-term liabilities	403	1
Total long-term liabilities	30,885	27,285
Total liabilities	37,023	31,641
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' DEFICIT:
Common stock, $.01 par value, 110,000 and 75,000 shares authorized, 34,097 and 28,677 issued and outstanding at December 31, 2019 and 2018, respectively	341	287
Warrants outstanding	1,330	1,810
Additional paid-in capital	367,015	364,885
Accumulated deficit	(401,783)	(392,292)
Total shareholders' deficit	(33,097)	(25,310)
Total liabilities and shareholders' deficit	$ 3,926	$ 6,331

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Consolidated Balance Sheets [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	110,000,000	75,000,000
Common stock, shares issued	34,097,000	28,677,000
Common stock, shares outstanding	34,097,000	28,677,000

Consolidated Statements Of Comp

Consolidated Statements Of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Loss on impairment of inventory	$ 6	$ 1,134
Gross margin	(5)	(1,102)
Research and development expenses	334	2,875
Selling, general and administrative expenses	7,602	10,427
Restructuring expenses		690
Total operating expenses	7,936	13,992
Interest and other income	3	2
Interest and other expense	(421)	(116)
Change in fair value of contingent payment obligation	(1,094)	(5,661)
Total interest and other	(1,512)	(5,775)
Net loss before income tax	(9,453)	(20,869)
Income tax expense
Net loss	(9,453)	(20,869)
Other comprehensive income, net of tax
Comprehensive loss	$ (9,453)	$ (20,869)
Basic and diluted net loss per common share	$ (0.30)	$ (0.85)
Weighted average common shares outstanding	31,461	24,429
Product [Member]
Revenue	$ 74	$ 135
Cost of sales	$ 73	$ 103

Consolidated Statements Of Shar

Consolidated Statements Of Shareholders Deficit - USD ($) $ in Thousands	Common Stock [Member]	Warrants Outstanding [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance, value at Dec. 31, 2017	$ 212	$ 826	$ 359,141	$ (371,423)	$ (11,244)
Issuance of common stock and warrants in public and private offerings, net of issuance costs	45	1,950	3,281		5,276
Issuance of common stock upon exercise of warrants	20	(475)	455
Expiration of warrants		(491)	491
Issuance of convertible debt with beneficial conversion feature			442		442
Issuance of common stock upon conversion and payment of interest in kind on convertible debt	4		52		56
Share-based compensation, net of shares withheld for taxes	6		1,023		1,029
Net loss for the year				(20,869)	(20,869)
Balance, value at Dec. 31, 2018	287	1,810	364,885	(392,292)	(25,310)
Issuance of common stock upon exercise of warrants	29	(660)	660		29
Issuance of common stock and warrants for services	6	180	54		240
Issuance of convertible debt with beneficial conversion feature			550		550
Issuance of common stock upon conversion and payment of interest in kind on convertible debt	19		277		296
Share-based compensation, net of shares withheld for taxes			589		589
Net loss for the year				(9,453)	(9,453)
Balance, value at Dec. 31, 2019	$ 341	$ 1,330	$ 367,015	(401,783)	(33,097)
Cumulative effect of change in accounting principle				$ (38)	$ (38)

Consolidated Statements Of Cash

Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,453)	$ (20,869)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	835	1,209
Share-based compensation	589	1,050
Noncash lease expense	280
Changes in fair value of contingent payment obligation	1,094	5,661
Loss on disposal of equipment and other assets	412	489
Inventory impairment charges	6	1,134
Changes in operating assets and liabilities:
Accounts receivable	2	25
Finished goods inventories	81	(207)
Prepaid expenses and other assets	221	62
Accounts payable and accrued expenses	2,790	1,034
Operating lease liabilities and deferred rent	(230)	115
Total adjustments	6,080	10,572
Net cash used in operating activities	(3,373)	(10,297)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from redemption of available-for-sale securities		26
Proceeds from sale of property and equipment	30	50
Purchases of property and equipment	(5)	(5)
Payments for patent costs and other intangible assets	(18)	(16)
Net cash provided by investing activities	7	55
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from issuance of common stock and warrants in public and private offerings		5,276
Net proceeds from exercise of options and warrants	29
Net proceeds from debt financings	3,068	5,294
Shares withheld for payment of taxes		(21)
Debt repayments	(1,200)	(132)
Principal payments on finance lease obligation	(1)	(2)
Net cash provided by financing activities	1,896	10,415
NET CHANGE IN CASH AND CASH EQUIVALENTS	(1,470)	173
CASH AND CASH EQUIVALENTS, beginning of year	1,527	1,354
CASH AND CASH EQUIVALENTS, end of year	57	1,527
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for interest	4	39
Cash paid for income taxes
SUPPLEMENTAL SCHEDULE OF NON-CASH ACTIVITIES:
Payment of interest in kind on convertible notes	$ 197	$ 26

Significant Accounting Policies

Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Significant Accounting Policies	1. SIGNIFICANT ACCOUNTING POLICIES  ParkerVision, Inc. and its wholly-owned German subsidiary, ParkerVision GmbH (collectively “ParkerVision”, “we” or the “Company”) is in the business of innovating fundamental wireless hardware technologies and products. We have determined that our business currently operates under a single operating and reportable segment.  We have designed and developed proprietary radio frequency (“ RF ”) technologies and integrated circuits for use in wireless communication products. We have expended significant financial and other resources to research and develop our RF technologies and to obtain patent protection for those technologies in the United States of America (“ U.S .”) and certain foreign jurisdictions. We believe certain patents protecting our proprietary technologies have been broadly infringed by others, and therefore the primary focus of our business plan is the enforcement of our intellectual property rights through patent infringement litigation and licensing efforts. We currently have patent enforcement actions ongoing in various U.S. district courts against mobile handset providers and their chip suppliers for the infringement of a number of our RF patents. We have made significant investments in developing and protecting our technologies, the returns on which are dependent upon the generation of future revenues for realization.  We also designed, developed and marketed a distributed WiFi product line under the brand name Milo ® . We restructured our operations during the third quarter of 2018 in order to reduce operating expenses in light of our limited capital resources. Accordingly, we significantly reduced our ongoing investment in the Milo product. In early 2019, we ceased substantially all ongoing research and development efforts and, where applicable, repurposed resources to support our patent enforcement and product sales and support efforts. We ceased sales of our Milo products in the fourth quarter of 2019.  Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U .S. (“ GAAP ”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts.  Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our secured contingent payment obligation, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation. Cash and Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased.  Inventory Inventory is stated at the lower of actual cost, as determined under the first-in, first-out method, or estimated net realizable value. We review our inventory for estimated obsolescence or unmarketable inventory and write down inventory for the difference between cost and estimated market value based upon assumptions about future demand. Future demand is affected by market conditions, technological obsolescence, new products and strategic plans, each of which is subject to change. Due to the decision to discontinue Milo product sales in the fourth quarter of 2019, a full reserve was recorded against the remaining inventory on hand at December 31, 2019.  Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives:     Manufacturing and office equipment 5 -7 years  Leasehold improvements Shorter of useful life or remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years  The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets.  Intangible Assets Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists.  Secured Contingent Payment Obligation We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ ASC ”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its estimated fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 10). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligation . ” Leases In February 2016, the FASB established ASC 842, “Leases” by issuing Accounting Standards Update (“ ASU ”) 2016-02 to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. ASC 842 was subsequently amended by ASU 2018-01, ASU 2018-10 and ASU 2018-11 which provided practical expedients for adoption of ASC 842. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. ASC 842 is effective for interim and annual periods beginning after December 15, 2018. A modified retrospective transition approach is required for adoption, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either the effective date or the beginning of the earliest comparative period presented in the financial statements as its date of initial application.  We adopted ASC 842 as of January 1, 2019, and we have elected to use the effective date as the initial application date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and period prior to January 1, 2019. The new standard provides a number of practical expedients in transition and we elected the package of practical expedients which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and treatment of initial direct costs. The adoption of this new standard resulted in the recognition of operating lease right-of-use (“ ROU ”) assets and operating lease liabilities of approximately $0.56 million and $0.60 million, respectively, primarily related to our facilities leases. Refer to Note 8 for additional disclosures related to our leases.  Revenue Recognition As of January 1, 2018, we adopted ASC 606, “Revenue from Contracts with Customers” which implements a common revenue standard that clarifies the principles for recognizing revenue. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The adoption of ASC 606 had no material effect on our consolidated financial statements .  We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes and sales of products. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when the performance obligations to our customers have been met. For the sale of products, the performance obligation is generally met at the time product is delivered to the customer. Estimated product returns are deducted from revenue and recorded as a liability. Revenue from the sale of our products includes shipping and handling charged to the customer. Product revenue is recorded net of sales tax collected from customers, discounts, and actual and estimated future returns.  The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded as revenue in our consolidated statements of comprehensive loss when our performance obligations related to each element have been met.  Shipping and Handling Costs Shipping and handling costs related to product sales for the years ended December 31, 2019 and 2018 were approximately $0.01 million each year. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.  Advertising Expense Advertising costs are expensed as incurred. Advertising expenses of approximately $0.04 million and $0.7 million for the years ended December 31, 2019 and 2018, respectively, are included in selling, general, and administrative expenses in the accompanying consolidated statements of comprehensive loss.  Research and Development Expenses Research and development costs are expensed as incurred and include salaries and benefits for employees engaged in research and development activities, costs paid to third party contractors, prototype expenses, an allocated portion of facilities costs, maintenance costs for software development tools, and depreciation.  Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“ RSUs ”) and restricted stock awards (“ RSAs ”). We calculate the fair value of employee share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur.  As of January 1, 2018, we adopted ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.” This update provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The adoption of this guidance did not have a material effect on our consolidated financial statements.  As of January 1, 2019, we adopted ASU 2018-07, "Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting." The amendments in this update simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. We did not previously have awards to nonemployees that would require reassessment and therefore the adoption of ASU 2018-07 did not impact our consolidated financial statements.  Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return.  As of January 1, 2019, we adopted ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.” The amendments in this update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. We have no stranded tax effects included in our other comprehensive loss and therefore the adoption of ASU 2018-02 did not impact our consolidated financial statements. Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive.  The number of shares underlying outstanding options, warrants, unvested RSUs, and convertible notes at December 31, 2019 and 2018 were as follows (in thousands):     2019 2018  Options outstanding 11,410 1,228  Warrants outstanding 12,150 13,279  Unvested RSUs - 14  Shares underlying convertible notes 20,846 2,746  44,406 17,267   These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive. 

Liquidity And Going Concern

Liquidity And Going Concern	12 Months Ended
	Dec. 31, 2019
Liquidity And Going Concern [Abstract]
Liquidity And Going Concern	2. LIQUIDITY AND GOING CONCERN  The accompanying consolidated financial statements as of and for the year ended December 31, 2019 were prepared assuming we will continue as a going concern, which contemplates that we will continue in operation and will be able to realize our assets and settle our liabilities and commitments in the normal course of business for a period of at least one year from the issuance date of these consolidated financial statements. These consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that could result should we be unable to continue as a going concern.  We have incurred significant losses from operations and negative cash flows in every year since inception and have utilized the proceeds from the sales of our equity and equity-linked securities and our contingent funding arrangements with third-parties to fund our operations, including our litigation costs. For the year ended December 31, 2019, we incurred a net loss of approximately $ 9.5 million and negative cash flows from operations of approximately $ 3.4 million. At December 31, 2019, we had a working capital deficit of approximately $5.5 million and an accumulated deficit of approximately $ 401.8 million. These circumstances raise substantial doubt about our ability to continue to operate as a going concern for a period of one year after the issuance date of these consolidated financial statements.  In 2018, we implemented significant cost reduction measures including cessation of our ongoing chip development activities, reductions in executive and key employee base salaries and curtailment of our spending for sales and marketing of our WiFi product line. We reduced costs further in 2019 with the downsizing of our corporate office facility and additional reductions in personnel and other operating costs. Our business plan is currently focused solely on our patent enforcement and technology licensing objectives. The timing and amount of proceeds from our patent enforcement actions are difficult to predict and there can be no assurance we will receive any proceeds from these enforcement actions.  Our ability to meet our liquidity needs for the twelve months after the issuance date of these financial statements is dependent upon one or more of (i) our ability to successfully negotiate licensing agreements and/or settlements relating to the use of our technologies by others in excess of our contingent payment obligations and (ii) our ability to raise additional capital from the sale of debt or equity securities or other financing arrangements. We anticipate that we will continue to invest in patent protection and licensing and enforcement of our wireless technologies. We expect that revenue generated from patent enforcement actions, and technology licenses over the twelve months after the issuance date of these financial statements, if any, after deduction of payment obligations to our third-party litigation funder and legal counsel, may not be sufficient to cover our operating expenses. In the event we do not generate revenues, or other patent-asset proceeds, sufficient to cover our operational costs and contingent repayment obligation, we will be required to raise additional working capital through the sale of equity securities or other financing arrangements.  During the first quarter of 2020, we received aggregate proceeds from the sale of debt and equity securities of approximately $1.6 million, proceeds from the exercise of outstanding warrants of approximately $0.5 million and advances from a potential litigation funding party of approximately $0.6 million. In addition, we repaid approximately $0.7 million in short-term debt and other accrued expenses through the use of shares of our common stock. Despite these funding efforts, our resources are not sufficient to meet our short-term liquidity needs and we will be required to seek additional capital.  The long-term continuation of our business plan is dependent upon our ability to secure sufficient financing to support our business, and our ability to generate revenues and/or patent-related proceeds sufficient to offset expenses and meet our contingent payment obligation and other long-term debt repayment obligations. Failure to generate sufficient revenues, raise additional capital through debt or equity financings, and/or reduce operating costs could have a material adverse effect on our ability to meet our short and long-term liquidity needs and achieve our intended long-term business objectives. 

Inventories

Inventories	12 Months Ended
	Dec. 31, 2019
Inventories [Abstract]
Inventories	3. INVENTORIES  Inventories consisted of the following at December 31, 2019 and 2018 (in thousands):     2019 2018  Raw materials $ - $ 139  Work-in-process - -  Finished goods 550 941  550 1,080  Inventory reserves (550) (982)  - 98  During the years ended December 31, 2019 and 2018, we recognized impairment charges to reduce our excess and obsolete inventories to their net realizable values. The following table provides a reconciliation of our inventory reserves for the years ended December 31, 2019 and 2018, respectively (in thousands):     2019 2018  Inventory reserves at beginning of year $ 982 $ -  Impairment charges 6 1,134  Write down of impaired inventories (438) (152)  Inventory reserves at end of year $ 550 $ 982  

Prepaid Expenses

Prepaid Expenses	12 Months Ended
	Dec. 31, 2019
Prepaid Expenses [Abstract]
Prepaid Expenses	4. PREPAID EXPENSES  Prepaid expenses consisted of the following at December 31, 2019 and 2018 (in thousands):     2019 2018  Prepaid services $ 221 $ 252  Prepaid bonds for German statutory costs 188 199  Prepaid insurance 62 19  Prepaid licenses, software tools and support 17 51  Other prepaid expenses 17 17  $ 505 $ 538  In 2018, we recorded impairment charges of approximately $0.4 million related to prepaid licenses and production tooling as a result of the restructuring of our operations. These charges are included in “Restructuring expenses” in the accompanying statements of comprehensive loss (see Note 15).

Property And Equipment, Net

Property And Equipment, Net	12 Months Ended
	Dec. 31, 2019
Property And Equipment, Net [Abstract]
Property And Equipment, Net	5. PROPERTY AND EQUIPMENT, NET  Property and equipment, at cost, consisted of the following at December 31, 2019 and 2018 (in thousands):     2019 2018  Equipment and software, including equipment purchased under capital leases of $6 and $17 at December 31, 2019 and 2018, respectively $ 260 $ 1,555  Leasehold improvements 33 786  Furniture and fixtures 43 182  336 2,523  Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $3 and $13 at December 31, 2019 and 2018, respectively (266) (2,394)  $ 70 $ 129   Depreciation expense related to property and equipment was approximately $0.04 million and $0.13 million in 2019 and 2018, respectively. Depreciation expense includes depreciation related to finance leases of approximately $0.001 million and $0.002 million for the periods ended December 31, 2019 and 2018, respectively. Our finance leases have original terms of one to three years. The principal payments for these finance leases are reflected as cash outflows from financing activities in the accompanying consolidated statements of cash flows. Future minimum lease payments under our capital leases that have initial terms in excess of one year are included in “Leases” in Note 8.  In connection with the relocation of our corporate headquarters in July 2019, we disposed of a number of assets that were no longer in use. For each of the years ended December 31, 2019 and 2018, we recorded a loss on disposal of fixed assets of approximately $0.01 million.  In connection with the closure of our Lake Mary facility in 2018, we reclassified equipment with a net book value of approximately $0.07 millio n to assets held for sale. We contracted with a third party for the consignment sale of these assets and completed sales for several assets in 2018 and 2019. For the year ended December 31, 2019, we recognized a net loss of approximately $0.04 million on the sale and/or impairment of assets held for sale. For the year ended December 31, 2018, we recognized a gain of approximately $0.01 million on assets held for sale. The gains and losses on the sale or impairment of held for sale assets is included in selling, general and administrative expenses in the accompanying statements of comprehensive loss.

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2019
Intangible Assets [Abstract]
Intangible Assets	6. INTANGIBLE ASSETS  Intangible assets consisted of the following at December 31, 2019 and 2018 (in thousands):     2019 2018   Patents and copyrights $ 16,612 $ 18,350  Less accumulated amortization (13,734) (14,448)  $ 2,878 $ 3,902   Amortization expense for each of the years ended December 31, 2019 and 2018 was approximately $0.6 million and $1.1 million, respectively. For the years ended December 31, 2019 and 2018, we recorded losses on the disposal of intangible assets of approximately $0.4 million and $0.1 million, respectively.  Future estimated amortization expense for intangible assets that have remaining unamortized amounts as of December 31, 2019 is as follows (in thousands):     2020 $ 473  2021 416  2022 373  2023 329  2024 303  2025 and thereafter 984  Total $ 2,878 

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2019
Accrued Liabilities [Abstract]
Accrued Liabilities	7. ACCRUED LIABILITIES  Other accrued expenses consisted of the following at December 31, 2019 and 2018 (in thousands):    2019 2018  Advances $ 500 $ -  Board compensation 413 413  Other accrued expenses 168 150  $ 1,081 $ 563   Advances are amounts received from litigation counsel as advanced reimbursement of out-of-pocket expenses expected to be incurred by us. Board compensation of $0.4 million at December 31, 2019 and 2018 represents accrued and unpaid board and committee fees from prior periods. In the first quarter of 2020, current and prior board members agreed to waive unpaid cash fees in exchange for share-based compensation awards with an aggregate grant-date fair value of approximately $0.1 million (see Note 18).

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Leases	8. LEASES  We lease our office and other facilities and certain office equipment under long-term, non-cancelable operating and finance leases. Many of our leases include rental escalation clauses, renewal options and/or termination options that are factored into our determination of lease payments when it is reasonably certain that the option will be exercised. For leases with terms greater than 12 months, we record the related asset and obligation at the present value of lease payments over the term. We do not recognize ROU assets and lease liabilities for leases with terms at inception of twelve months or less. At inception, we determine if an arrangement contains a lease and whether that lease meets the classification criteria of a finance or operating lease. Some of our lease arrangements contain lease components (e.g. minimum rent payments) and non-lease components (e.g. services). For certain equipment leases, we account for lease and non-lease components separately based on a relative fair market value basis. For all other leases, we account for the lease and non-lease components (e.g. common area maintenance) on a combined basis.  Following the adoption of ASC 842 as of January 1, 2019 (see Note 1), operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities on the consolidated balance sheets. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term using the implicit interest rate, when readily available, or our incremental borrowing rate for collateralized debt based on information available at the lease commencement date. Lease expense for operating leases is generally recognized on a straight-line basis over the lease term and is included in operating expenses on the consolidated statement of comprehensive loss. For the year ended December 31, 2019, we recognized operating lease costs of approximately $0.4 million. Finance leases are included in property and equipment and other accrued expenses on the consolidated balance sheets. Finance leases are recorded as an asset and an obligation at an amount equal to the present value of the minimum lease payments during the lease term. Amortization expense and interest expense associated with finance leases are included in selling, general, and administrative expense and interest expense, respectively, on the consolidated statements of comprehensive loss. Finance leases are not material to our consolidated financial statements as of or for the year ended December 31, 2019.  No new finance or operating leases commenced during the year ended December 31, 2019.  Supplemental Cash Flow Information  The following table summarizes the supplemental cash flow information related to leases, including the ROU assets recognized upon adoption of the new lease standard (in thousands):    Year Ended  December 31,  2019  Cash paid for amounts included in the measurement of lease liabilities:  Operating cash flows from operating leases $ 314  Operating cash flows from finance leases -  Financing cash flows from finance leases 1   Non-cash activity  Right-of-use assets obtained in exchange for operating lease liabilities 563  Assets obtained in exchange for finance lease liabilities -   Other Information  The table below summarizes other supplemental information related to leases:     December 31,  2019  Weighted-average remaining lease term (in years):  Operating leases 2.7  Finance leases 0.3  Weighted average discount rate  Operating leases (1) 12.0%  Finance leases 8.7%  (1) Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.  Undiscounted Cash Flows  The future maturities of lease liabilities consist of the following as of December 31, 2019 (in thousands) :     Operating Leases Finance Leases  2020 $ 295 $ 1  2021 176 -  2022 166 -  2023 4 -  Thereafter - -  Total undiscounted lease payments 641 1  Less: imputed interest (86) -  Present value of lease liabilities 555 1  Less: current obligations under leases (250) (1)  Long-term lease obligations $ 305 $ -   Disclosures related to periods prior to adoption of the new lease standard  Lease Commitments The following table presents a summary of our facilities under non-cancelable lease agreements at December 31, 2018:      Description Lease Start Date Lease End Date Renewal options remaining Straight line monthly rental payment (in thousands)  Corporate office, Jacksonville, Florida 7/15/2018 7/31/2019 none $ 31  Wireless design facility, Lake Mary, Florida 7/1/2017 11/30/2022 2 options to extend for 36 months each $ 13  Warehouse and production facility, Jacksonville, Florida 7/1/2017 7/31/2020 none $ 2   Deferred rent is amortized to rent expense over the respective lease terms. In addition to sales tax payable on base rental amounts, certain leases obligate us to pay pro-rated annual operating expenses for the properties. Rent expense for our facilities for the year ended December 31, 2018, was approximately $0.5 million.  Contractual obligations Future minimum lease payments under all non-cancelable operating leases and capital leases that have initial terms in excess of one year as of December 31, 2018 were as follows (in thousands):     Contractual obligations: 2019 2020 2021 and thereafter Total  Operating leases $ 372 $ 191 $ 345 $ 908  Capital leases $ 2 $ 1 $ - $ 3   Our contractual obligations as of December 31, 2018 for operating leases include approximately $0.7 million related to our Lake Mary, Florida facility. We ceased use of this facility in 2018 and at December 31, 2018, we have recorded a lease liability of $0.2 million which reflects the estimated net present value of our Lake Mary lease obligation, net of estimated future sublease rental income (see Note 15).

Long-Term Debt

Long-Term Debt	12 Months Ended
	Dec. 31, 2019
Long-Term Debt [Abstract]
Long-Term Debt	9. LONG-TERM DEBT  Notes Payable  Note Payable to a Related Party We have an unsecured promissory note payable of $0.9 million to Sterne, Kessler, Goldstein, & Fox, PLLC (“ SKGF ”), a related party (see Note 16), for outstanding unpaid fees for legal services . The SKGF n ote, as amended in 2018, accrued interest at a rate of 8% per annum and provided for payments of principal and interest of approximately $48,500 per month commencing October 31, 2018 through March 31, 2020 . At December 31, 2018, we were in default on the payment terms of the SKGF n ote. In March 2019, we amended the n ote to provide for a waiver of past payment defaults, a decrease in the interest rate from 8% per annum to 4% per annum, an extension of the maturity date from March 2020 to April 2022 , and a modification of payment terms. This amendment constituted a troubled debt restructuring and was accounted for on a prospective basis from the date of the amendment. As of June 29, 2019, we amended the note to provide for a postponement of past payment defaults and future payments until October 2019. In October 2019, we further amended the note to provide a continued waiver of any payment defaults and to modify the payment schedule such that repayments of principal and interest commence January 31, 2020 at a rate of $10,000 per month with a final balloon payment due in April 2022 . We are currently in compliance with all the terms of the note , as amended. For the years ended December 31, 2019 and 2018, we recognized interest expense of approximately $0.04 million and $0.06 million, respectively , related to this note .  Unsecured Short - Term Notes Payable In May and June 2019, we entered into short-term promissory notes with accredited investors for aggregate proceeds of approximately $0.23 million. The notes were unsecured, accrued interest at a rate of 18% per annum and had an original maturity date at the earlier of ninety (90) days following the issuance date or upon our receipt of additional litigation financing. Subsequently, t he maturity date for the notes was extended to December 2019 and the interest rate was increased to 20% per annum. In the first quarter of 2020, we issued an aggregate of 1,740,426 shares of our common stock as an in-kind repayment of all outstanding principal and accrued interest on these short-term notes (see Note 18). Interest expense incurred on these short-term notes for the year-ended December 31, 2019, was approximately $0.03 million.  Secured Note Payable We have a note payable to Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. (“ Mintz ”) for outstanding, unpaid attorney’s fees and costs associated with our patent enforcement program. The Mintz n ote is non-interest bearing, except in the event of a default, and is secured by certain of our U.S. and foreign patents. The n ote , at Mintz’s option, accelerates and becomes immediately due and payable in the case of standard events of default and/or in the event of a sale or other transfer of substantially all of our assets or a transfer of more than 50% of our capital stock in one or a series of transactions or through a merger or other similar transaction. In an event of default, the n ote will accrue interest at a rate of 12% per annum on any outstanding balance until such time that the note is paid in full.  The Mintz no te provided for an initial installment of $0.1 million upon execution and monthly installments of $0.2 million beginning November 2018 . We repaid an aggr egate of $ 1.2 million and $0.1 million in 2019 and 2018, respectively, and therefore failed to meet our payment obligations under the Mintz note. Mintz waived past and future payment defaults, an increase in the default interest rate to 12 % and acceleration of unpaid principal and interest through November 16 , 2019 , provided that no other event of default occurred . As of December 31, 2019, we were in payment default under the note, and accordingly, the note balance at December 31 , 2019 includes approximately $0.02 million in default interest. We are in active discussions with Mintz to cure the default and resolve outstanding fees, including approximately $1.6 million included in accounts payable at December 31, 2019, which are currently in dispute. Currently, Mintz has not requested acceleration of unpaid principal and interest on the note, nor have they waived the outstanding default. In the first quarter of 2020, we paid Mintz an aggregate of approximately $1.2 million against outstanding amounts owed to them.  At December 31, 2019, the aggregate maturities of our notes payable are as follows (in thousands):      2020 $ 1,533  2021 90  2022 703  Total $ 2,326   The estimated fair value of our notes payable at December 31, 2019 is approximately $2.2 million based on a risk-adjusted discount rate.  Convertible Notes  In 2019 and 201 8 , we sold five -year convertible promissory notes for aggregate proceeds of approximately $2.4 million and $1.3 million , respectively. Our convertible notes represent five-year promissory notes that are convertible, at the holders’ option, into shares of our common stock at fixed conversion prices. Interest payments are made on a quarterly basis and are payable, at our option and subject to certain equity conditions, in either cash, shares of our common stock, or a combination thereof. To date, all interest payments on the convertible notes have been made in shares of our common stock. We have recognized the convertible notes as debt in our consolidated financial statements. The fixed conversion prices of certain of the notes were below market value of our common stock on the closing date resulting in a beneficial conversion feature with a value of approximately $0.6 million and $0.4 million for the years ended December 31, 2019 and 2018 , respectively . The beneficial conversion feature is recorded as a discount on the convertible notes with a corresponding increase to additional paid in capital.  Convertible notes payable at December 31, 2019 and 2018, consist of the following (in thousands):     Fixed Effective  Conversion Interest December 31,  Description Rate Rate Maturity Date 2019 2018  Convertible notes dated September 10, 2018 $0.40 8.3% September 7, 2023 $ 700 $ 800  Convertible notes dated September 19, 2018 $0.57 8.3% September 19, 2023 425 $ 425  Convertible notes dated February/March 2019 $0.25 8.0% February 28, 2024 to March 13, 2024 1,300 -  Convertible notes dated June/July 2019 $0.10 8.0% June 7, 2024 to July 15, 2024 390 -  Convertible notes dated July 18, 2019 $0.08 46.1% July 18, 2024 700 -  Convertible notes dated September 13, 2019 $0.10 25.9% September 13, 2024 50 -  Total principal balance 3,565 1,225  Less unamortized discount 832 388  $ 2,733 $ 837   The July 18, 2019, notes bear interest at a stated rate of 7.5% per annum, while all other notes bear interest at a stated rate of 8% per annum. Interest is payable quarterly and we may elect to pay interest in either cash, shares of our common stock, or a combination thereof, subject to certain equity conditions. For the years ended December 31, 2019 and 2018, we recognized interest expense of approximately $0.32 million and $0.05 million, respectively, including approximately $0.1 million and $0.02 million, respectively, related to amortization of the discount and $0.22 million and $0.03 million, respectively, related to the contractual interest which we elected to pay in shares of our common stock. The unamortized discount on the convertible notes will be amortized over a remaining period of approximately 4.15 years.  The shares underlying the 2018 convertible notes, as well as shares reserved for future in-kind interest payments on the notes, were registered on a registration statement that was declared effective on November 13, 2018 (File No. 333-228184). The shares underlying the February and March 2019 convertible notes, as well as shares reserved for future in-kind interest payments on the notes, were registered on a registration statement that was declared effective on April 19, 2019 (File No. 333-230888). The shares underlying the June and July 2019 convertible notes, as well as shares reserved for future in-kind interest payments on the notes, were registered on a registration statement that was declared effective on September 11, 2019 (File No. 333-233390).  At the holders’ option, the convertible notes outstanding at December 31, 2019 could be converted into an aggregate of approximately 20.8 million shares of our common stock based on the fixed conversion prices. A n aggregate of $0.1 mi llion in outstanding principal was converted by the holders into 0.25 million shares of our common stock at a fixed conversion price of $0.40 for each of the years ended December 31, 2019 and 2018.  With the exception of the July 2019 notes, we have the option to prepay the notes any time following the one-year anniversary of the issuance of the notes, subject to a premium on the outstanding principal prepayment amount of 25% prior to the two-year anniversary of the note issuance date, 20% prior to the three-year anniversary of the note issuance date, 15% prior to the four-year anniversary of the note issuance date, or 10% thereafter. The notes provide for events of default that include failure to pay principal or interest when due, breach of any of the representations, warranties, covenants or agreements made by us, events of liquidation or bankruptcy, and a change in control. In the event of default, the interest rate increases to 12% per annum and the outstanding principal balance of the notes plus all accrued interest due may be declared immediately payable by the holders of a majority of the then outstanding principal balance of the notes.  Secured Contingent Payment Obligation  The following table provides a reconciliation of our secured contingent payment obligation measured at estimated fair market value for the year ended December 31, 2019 and 2018, respectively (in thousands).      2019 2018  Secured contingent payment obligation, beginning of year $ 25,557 $ 15,896  Proceeds from contingent payment obligation - 4,000  Change in fair value 1,094 5,661  Secured contingent payment obligation, end of year $ 26,651 $ 25,557   Our secured contingent payment obligation represents the estimated fair value of our repayment obligation to Brickell Key Investments, LP (“ Brickell ”) under a February 2016 funding agreement, as amended from time to time (the “ CPIA ”). To date, we have received aggregate proceeds of $18 million, including $4.0 million received in 2018, in exchange for Brickell’s right to reimbursement and compensation from gross proceeds resulting from patent enforcement and other patent monetization actions. No additional proceeds were received from Brickell in 2019. To date, we have repaid an aggregate of $3.3 million under the CPIA from patent license and settlement proceeds.  In connection with additional proceeds received in December 2018, we issued Brickell a warrant to purchase up to 5.0 million shares of our common stock at an exercise price of $0.16 per share (see Note 13). As the estimated fair value of the payment obligation to Brickell resulting from this additional funding exceeded the $2.5 million in proceeds received, no value was assigned to the warrants. The excess of fair value over the proceeds received of approximately $0.8 million was included in the change in fair value of our contingent payment obligation in the accompanying consolidated statement of comprehensive loss for the year ended December 31, 2018.  Brickell is entitled to priority payment of 55% to 100% of proceeds received from all patent-related actions until such time that Brickell has been repaid in full. After repayment of the funded amount, Brickell is entitled to a portion of remaining proceeds up to a specified minimum return which is determined as a percentage of the funded amount and varies based on the timing of repayment. In addition, Brickell is entitled to a pro rata portion of proceeds from specified legal actions to the extent aggregate proceeds from those actions exceed the specified minimum return.  Brickell holds a senior security interest in the majority of our assets until such time as the specified minimum return is paid, in which case, the security interest will be released except with respect to the patents and proceeds related to specific legal actions. The security interest is enforceable by Brickell in the event that we are in default under the agreement which would occur if (i) we fail, after notice, to pay proceeds to Brickell, (ii) we become insolvent or insolvency proceedings are commenced (and not subsequently discharged) with respect to us, (iii) our creditors commence actions against us (which are not subsequently discharged) that affect our material assets, (iv) we, without Brickell’s consent, incur indebtedness other than immaterial ordinary course indebtedness, or (v) there is an uncured non-compliance of our obligations or misrepresentations under the agreement. As of December 31, 2019, we are in compliance with our obligations under this agreement.  In addition, in the event of a change in control of the Company, Brickell has the right to be paid its return as defined under the CPIA based on the transaction price for the change in control event.  We have elected to measure our secured contingent payment obligation at fair value based on probability-weighted estimated cash outflows, discounted back to present value using a discount rate determined in accordance with accepted valuation methods (see Note 10). The secured contingent payment obligation is remeasured to fair value at each reporting period with changes recorded in the consolidated statements of comprehensive loss until the contingency is resolved.  Other Liabilities  Other liabilities include $0.4 million received from a third-party litigation funder as an advance against a funding transaction that was under negotiation. Upon the consummation of a financing transaction with the third-party, the upfront payment would be credited against the financing which is expected to be accounted for as a contingent payment obligation at fair value. If we fail to consummate a funding transaction, we may be obligated to pay , from future patent-related proceeds, an aggregate termination payment equal to five times the upfront payment received. At December 31, 2019, we believe the carrying value of the liability approximates fair value.  We received an additional $0.6 million in January 2020 from this funder for an aggregate of $1.0 million in upfront payments. In April 2020, we ceased negotiations with the third-party and, accordingly, we may be obligated to pay a termination fee of up to $5 million from future patent-related proceeds.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Fair Value Measurements [Abstract]
Fair Value Measurements	10. FAIR VALUE MEASUREMENTS  ASC 820, “Fair Value Measurements” establishes a fair value hierarchy that prioritizes the inputs to valuation methods used to measure fair value. The three levels of the fair value hierarchy are as follows:  · Level 1: Quoted prices for identical assets or liabilities in active markets which we can access · Level 2: Observable inputs other than those described in Level 1 · Level 3: Unobservable inputs  The following table summarizes financial assets and financial liabilities carried at fair value and measured on a recurring basis as of December 31, 2019 and 2018, segregated by classification within the fair value hierarchy (in thousands):     Fair Value Measurements  Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  December 31, 2019:  Liabilities:  Secured contingent payment obligation $ 26,651 $ - $ - $ 26,651    December 31, 2018:  Liabilities:  Secured contingent payment obligation 25,557 - - 25,557  For the years ended December 31, 2019 and 2018, respectively, we had no transfers of assets or liabilities between the levels of the hierarchy.  In 2016, we recognized a secured contingent payment obligation upon our receipt of proceeds from Brickell for funding of certain patent-related actions. The fair value of the contingent payment obligation at December 31, 2019 and 2018 was estimated at $26.7 million and $25.6 million, respectively. These values were calculated using a probability-weighted income approach based on various cash flow scenarios as to the outcome of patent-related actions both in terms of timing and amount, discounted to present value using a risk-adjusted rate. The contingent payment obligation does not have a fixed duration; however, our cash flow projections assume a duration through 2022. The assumed cash outflows range from $0 to $58.8 million and the cash flow scenarios have probabilities of 5% to 25% . We used a risk-adjusted discount rate of approximately 15.6% , based on a two year risk-free rate of approximately 1.6% as adjusted by 8% for credit risk and 6% for litigation inherent risk. Changes in any of these Level 3 inputs could result in a higher or lower fair value measurement. For example, a decrease in the risk-adjusted discount rate from 15.6% to 8% would result in an increase in the fair value of approximately $3.9 million. Refer to Note 9 for a reconciliation of our secured contingent payment obligation measured at estimated fair value for the years ended December 31, 2019 and 2018.

Income Taxes And Tax Status

Income Taxes And Tax Status	12 Months Ended
	Dec. 31, 2019
Income Taxes And Tax Status [Abstract]
Income Taxes And Tax Status	11. INCOME TAXES AND TAX STATUS  Our net losses before income taxes for the years ended December 31, 2019 and 2018 are from domestic operations as well as losses from our wholly-owned German subsidiary. We elected to treat our German subsidiary as a disregarded entity for purposes of income taxes and accordingly, the losses from our German subsidiary has been included in our operating results.  No current or deferred tax provision or benefit was recorded in 2019 or 2018 as a result of current losses and fully deferred tax valuation allowances for all periods. We have recorded a valuation allowance to state our deferred tax assets at their estimated net realizable value due to the uncertainty related to realization of these assets through future taxable income.  A reconciliation between the provision for income taxes and the expected tax benefit using the federal statutory rate of 21% for each of the years ended December 31, 2019 and 2018, respectively are as follows (in thousands):     2019 2018  Tax benefit at statutory rate $ (1,985) $ (4,382)  State tax benefit (407) (897)  Increase in valuation allowance 2,341 5,304  Research and development credit - (51)  Other 51 26  $ - $ -   Our deferred tax assets and liabilities relate to the following sources and differences between financial accounting and the tax bases of our assets and liabilities at December 31, 2019 and 2018 (in thousands):     2019 2018  Gross deferred tax assets:  Net operating loss carry-forward $ 83,865 $ 84,192  Research and development credit 7,608 7,879  Stock compensation (28) 1,027  Patents and other 1,479 1,495  Contingent payment obligation 3,119 2,842  Inventories 139 249  Fixed assets 2 25  Accrued liabilities 200 146  Deferred rent and lease liabilities 142 46  Charitable contributions 1 5  Capital loss carry-forward - 3  Warranty reserve 3 4  96,530 97,913  Less valuation allowance (96,320) (97,816)  210 97  Gross deferred tax liabilities:  Convertible debt (210) (97)  (210) (97)  Net deferred tax asset $ - $ -   Approximately $0.2 million, net of tax effect, of unrecognized tax benefit related to the beneficial conversion feature of convertible debt would be recorded as an adjustment to contributed capital rather than a decrease in earnings, if recognized.  At December 31, 2019, we had cumulative net operating loss (“ NOL ”) carry-forwards for income tax purposes of $335.1 million, of which $314.8 million is subject to expiration in varying amounts from 2020 to 2037 . At December 31, 2019, we also had research and development tax credit carryforwards of $7.6 million, which expire in varying amounts from 2020 through 2038 .  Our ability to benefit from the tax credit carry-forwards could be limited under certain provisions of the Internal Revenue Code if there are ownership changes of more than 50%, as defined by Section 382 of the Internal Revenue Code of 1986 (“ Section 382 ”). Under Section 382, an ownership change may limit the amount of NOL, capital loss and R&D credit carry-forwards that can be used annually to offset future taxable income and tax, respectively. In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50 percentage points over a three-year period. We conduct a study annually of our ownership changes. Based on the results of our studies, we have determined that we do not have any ownership changes on or prior to December 31, 2019 which would result in limitations of our NOL, capital loss or R&D credit carry-forwards under Section 382.  Uncertain Tax Positions We file income tax returns in the U.S. federal jurisdiction , various state jurisdictions , and Germany . We have identified our Federal and Florida tax returns as our only major jurisdictions, as defined. The periods subject to examination for those returns are the 2000 through 2019 tax years. The following table provides a reconciliation of our unrecognized tax benefits due to uncertain tax positions for the years ended December 31, 2019 and 2018, respectively (in thousands):     2019 2018  Unrecognized tax benefits – beginning of year $ 927 $ 927  Unrecognized tax benefits – end of year $ 927 $ 927   Future changes in the unrecognized tax benefit will have no impact on the effective tax rate so long as we maintain a full valuation allowance.  Our policy is that we recognize interest and penalties accrued on any unrecognized tax benefits as a component of our income tax expense. We do not have any accrued interest or penalties associated with any unrecognized tax benefits. For the years ended December 31, 2019 and 2018, we did not incur any income tax-related interest income, expense or penalties.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies [Abstract]
Commitments And Contingencies	12. COMMITMENTS AND CONTINGENCIES  Legal Proceedings From time to time, we are subject to legal proceedings and claims which arise in the ordinary course of our business. These proceedings include patent enforcement actions initiated by us against others for the infringement of our technologies, as well as proceedings brought by others against us at the Patent Trial and Appeal Board of the U.S. Patent and Trademark Office (“ PTAB ”) and in the Federal Patent Court in Germany in an attempt to invalidate certain of our patent claims. We ha d several patent enforcement actions in Germany, which has a “loser pay” system whereby the non-prevailing party is responsible for statutory attorney fees and costs. To the extent a loss is probable and reasonably estimable as of the balance sheet date, the estimated loss is recorded in the accompanying consolidated statements of comprehensive loss and included in current liabilities under the heading “statutor y court costs” in the consolidated balance sheets. As of December 31, 2019 and 2018, we have accrued an aggregate of $0.37 million and $0.11 million, respectivel y in estimated statutory court costs for our cases in Germany.  ParkerVision v. Qualcomm and HTC (Middle District of Florida) We have a patent infringement complaint pending in the Middle District of Florida against Qualcomm and Qualcomm Atheros, Inc. (collectively “ Qualcomm ”), and HTC (HTC Corporation and HTC America, Inc.) (the “ Qualcomm Action ”) seeking unspecified damages and injunctive relief for infringement of certain of our patents. Certain of the defendants have filed counterclaims against us for non-infringement and invalidity for all patents in the case. The case was filed in May 2014 and stayed in February 2016 pending decisions in other cases, including the appeal of a PTAB proceeding with regard to U.S. patent 6,091,940 (“ the ‘940 Patent ”) asserted in this case. In September 2018, the Federal Circuit issued its decision with regard to the ‘940 Patent and, in January 2019, the court lifted the stay in this case. In July 2019, the court issued an order that granted our proposed selection of patent claims from four asserted patents, including the ‘940 Patent, and denied Qualcomm’s request to limit the claims and patents. The court also agreed that we may elect to pursue accused products that were at issue at the time the case was stayed, as well as new products that were released by Qualcomm during the pendency of the stay. In September 2019, Qualcomm filed a motion for partial summary judgement in an attempt to exclude certain patents from the case, including the ‘940 Patent. The court denied this motion in January 2020. A c laim construction hearing w as held in this case in August 2015, prior to the stay, and a second claim construction hearing was held in November 2019. The court has not yet issued its claim construction order. This case is scheduled for trial beginning December 1, 2020. On March 16, 2020, in response to the impact of COVID-19, the parties filed a motion requesting a stay of all deadlines and discovery responses for a period of four weeks, or until April 14, 2020, at which time the situation will be assessed as to whether an additional stay or extension of the case schedule is required. The law firm of McKool Smith is representing us in this case on a contingency fee basis.  Qualcomm v. ParkerVision – PTAB In August 2015, Qualcomm filed an aggregate of ten petitions for Inter Partes Review (“ IPR ”) with the PTAB seeking to invalidate certain claims related to three of the eleven patents originally asserted in our Qualcomm Action. The PTAB denied institution of three of the petitions, all of which relate to our U.S. patent 7,039,372 (“ the ‘372 Patent ”). We filed a motion to disclaim the challenged claims of U.S. patent 7,966,012 (“ the ‘012 Patent ”) and, accordingly, the PTAB entered an adverse judgment against us with respect to the one petition pertaining to the ‘012 Patent. In March 2017, the PTAB issued its decisions on the six outstanding IPRs, all of which relate to the ‘940 Patent. The PTAB ruled in our favor on three of the six petitions, ruled in Qualcomm’s favor on two of the six petitions and issued a split decision on the claims covered in the sixth petition. As a result of the PTAB decisions, certain claims of the ‘940 Patent were found to be un-patentable and certain claims were found not to be un-patentable. In May 2017, we filed a notice of appeal of these decisions with the U.S. Court of Appeals for the Federal Circuit (“ CAFC ”). Qualcomm also appealed the decisions that were unfavorable to them. On September 13, 2018, the CAFC upheld the PTAB ruling with regard to the ‘940 Patent. As a result of the ruling, we prevailed with regard to the method claims of the ‘940 Patent and Qualcomm prevailed on the apparatus claims. This matter is now closed although the patents at issue in this proceeding are the subject of the Qualcomm Action discussed above.  ParkerVision v. Apple and Qualcomm (Middle District of Florida) In December 2015, we filed a patent infringement complaint in the Middle District of Florida against Apple, LG, Samsung and Qualcomm alleging infringement of four of our patents. In February 2016, the district court proceedings were stayed pending resolution of a corresponding case filed at the International Trade Commission (“ ITC ”) . In July 2016, we entered into a patent license and settlement agreement with Samsung and, as a result, Samsung was dismissed from the district court action. In March 2017, we filed a motion to terminate the ITC proceedings and a corresponding motion to lift the stay in the district court case. This motion was granted in May 2017. In July 2017, we filed a motion to dismiss LG from the district court case (see ParkerVision v. LG below). Also in July 2017, Qualcomm filed a motion to change venue to the southern district of California and Apple filed a motion to dismiss for improper venue. In March 2018, the district court ruled against the Qualcomm and Apple motions. The parties also filed a joint motion in March 2018 to eliminate three of the four patents in the case in order to expedite proceedings leaving our U.S. patent 9,118,528 as the only remaining patent in this case. A claim construction hearing was held on August 31, 2018. In July 2019, the court issued its claim construction order in which the court adopted our proposed claim construction for two of the six terms and the “plain and ordinary meaning” on the remaining terms. In addition, the court denied a motion filed by Apple for summary judgment. Fact discovery has closed in this case and a jury trial is scheduled to begin in August 2020. In March 2020, as a result of the impact of COVID-19, the parties filed a motion requesting an extension of certain deadlines in the case. Although currently a request has not been made to change the trial date, the parties plan to file a joint status report in April 2020, at which time the situation will be assessed as to whether additional modifications to the case schedule will be required.  ParkerVision v. LG (District of New Jersey) In July 2017, we filed a patent infringement complaint in the district of New Jersey against LG for the alleged infringement of the same patents previously asserted against LG in the middle district of Florida (see ParkerVision v. Apple and Qualcomm above). We elected to dismiss the case in the middle district of Florida and re-file in New Jersey as a result of a Supreme Court ruling regarding proper venue. In March 2018, the court stayed this case pending a final decision in ParkerVision v. Apple and Qualcomm in the Middle District of Florida. As part of this stay, LG has agreed to be bound by the final claim construction decision in that case.  ParkerVision v. LG Electronics (Munich, Germany) In June 2016, we filed a complaint in Munich District Court against LG Electronics Deutschland GmbH, a German subsidiary of LG Electronics, Inc. (“ LGE ”) seeking damages and injunctive relief for the alleged infringement of the German part of our European patent 1 206 831 (“ the ‘831 Patent ”). A hearing in this case was held in November 2016 at which time the court concluded that certain LGE products using Qualcomm RF circuitry infringe our patent. The final decision in this case was stayed pending resolution of the corresponding nullity, or validity, action filed by Qualcomm in the German Federal Patent Court in Munich (see Qualcomm v. ParkerVision below). In October 2018, we received an unfavorable decision in the nullity case for which we filed an appeal. In July 2019, we withdrew our appeal. As a result, our complaint in this case was dismissed, and we are subject to a claim reimbursement of statutory attorney’s fees and costs in this case which we have accrued in the accompanying consolidated financial statements as of December 31, 2019. We have posted a bond to cover this cost which is included in “Prepaid expenses” in the accompanying consolidated balance sheets.  ParkerVision v. Apple (Munich, Germany) - the Apple I case In October 2016, we filed a complaint in Munich District Court against Apple, Inc., Apple Distribution International, and Apple Retail Germany B.V. & Co. KG (collectively “ Apple ”) seeking damages and injunctive relief for the alleged infringement of the ‘831 Patent (the “ Apple I Case ”). In February 2017, we amended our complaint adding the infringement of a second German patent and alleging infringement by Apple devices that incorporate an Intel transceiver chip. The Munich Regional Court bifurcated the new claims into a second case (see ParkerVision v. Apple - the Apple II case below). A hearing was held in May 2017 in the Apple I Case. In June 2017, the court deferred its ruling pending the decision from the German Federal Patent Court in the validity action filed by Qualcomm (see Qualcomm v. ParkerVision below). In October 2018, we received an unfavorable decision in the Qualcomm nullity case for which we filed an appeal which we subsequently withdrew. We opted not to post a bond to cover the potential statutory costs in this case. As a result, in March 2019, the district court declared the complaint withdrawn, a decision we opted not to appeal. In October 2019, we paid statutory attorney’s fees and costs totaling approximately $0.06 million. This matter is now closed.  Qualcomm v. ParkerVision – Federal Patent Court in Germany (as appealed to the German Supreme Court) In August 2016, Qualcomm filed a validity action in Federal Patent Court in Germany against the ’831 Patent. The outcome of this validity action impacts our German patent infringement cases against LGE and Apple as discussed above. On October 17, 2018, following an oral hearing, the court ruled that the ‘831 Patent was invalid. Accordingly , we recorded a contingent loss for the estimated statutory fees and costs in this case as of December 31, 2018. In January 2019, we appealed this decision to the German Supreme Court, but withdrew our appeal in July 2019. As a result, we are subject to statutory fees and costs in this case, which are accrued in the accompanying consolidated financial statements.  ParkerVision v. Apple (Munich, Germany) – the Apple II case The Apple II case sought damages and injunctive relief for the alleged infringement of the German part of our European patent 1 135 853 (“the ‘ 853 Patent ”). A preliminary hearing was held in November 2017. Subsequent to the hearing, the court requested that we supplement certain elements of the infringement claims against Apple devices. In May 2018, we filed our supplemental briefs as requested by the court. In October 2018, we also filed a supplemental expert report. The court appointed an expert in this case and a hearing was held in March 2019 for purposes of providing expert testimony. The court ruled in April 2019 that Apple does not infringe our ‘853 Patent. We did not appeal this decision. As a result, we are subject to a claim for reimbursement of statutory attorney’s fees and costs in this case which we have accru ed in the accompanying consolidated financial statements as of December 31, 2019. We have posted a bond to cover this cost which is included in “Prepaid expenses” in the accompanying consolidated balance sheets.  Intel v. ParkerVision (Federal Patent Court in Germany) In August 2017, Intel filed a nullity action in German Federal Patent Court claiming invalidity of the ‘853 Patent that is the subject of the Apple II case. In December 2019, following the adverse decision in the Apple II case, we elected not to proceed with a defense in this case. In December 2019, the Federal Patent Court determined that we will bear the costs for statutory attorney fees and costs in this case as the non-prevailing party. Accordingly, we have accrued a contingent loss of statutory fees and costs in the accompanying consol idated financial statements as of December 31, 2019.  ParkerVision v. Intel (Western District of Texas) In February 2020, we filed a patent infringement complaint in the Western District of Texas against Intel alleging infringement of eight of our patents. The law firm of Gold berg Segalla is representing us in this case on a contingency fee basis. 

Stock Authorization And Issuanc

Stock Authorization And Issuance	12 Months Ended
	Dec. 31, 2019
Stock Authorization And Issuance [Abstract]
Stock Authorization And Issuance	13. STOCK AUTHORIZATION AND ISSUANCE Preferred Stock We have 15 million shares of preferred stock authorized for issuance at the direction of the board of directors (the “ Board ”). On November 17, 2005, our Board designated 0.1 million shares of authorized preferred stock as the Series E Preferred Stock in conjunction with its adoption of a Shareholder Protection Rights Agreement. As of December 31, 2019, we had no outstanding preferred stock.  Common Stock We have 110 million shares of common stock authorized for issuance. Our shareholders approved amendments to our articles of incorporation in June and October 2018, increasing the number of authorized shares of common stock to 40 million and 75 million shares, respectively . In November 2019, our shareholders approved an amendment to our articles of incorporation to increase the number of our authorized shares of common stock from 75 million to 110 million shares.  As of December 31, 2019, we have 23.6 million s hares reserved for issuance under outstanding warrants and options, 2.1 million shares reserved for future issuance under equity compensation plans, and 20.8 million and 7.2 million shares reserved for the conversion of principal and the payment of interest in-kind, respectively, under outstanding convertible notes.  Stock and Warrant Issuances – Equity Based Financings During the year ended December 31, 2019, the only equity-based financings were the sale of convertible notes (see Note 9). The following table presents a summary of completed equity-based financings for the years ended December 31, 2018 (in thousands, except for per share amounts):     Date Transaction # of Common Shares/ Units Sold Average Price per Share/Unit # of Warrants Issued (in 000’s) Average Exercise Price per Warrant Net Proceeds (1)  July 2018 and September 2018 Offerings under PIPE Agreement - - 10,000 $0.38 $ 1,901  March 2018 Director Stock Purchase 217 $0.83 - - $ 180  March - May 2018 Offerings under ATM 1,359 $0.87 - - $ 1,148  January - June 2018 Offerings under Equity Line Agreement 2,940 $0.70 - - $ 2,047  (1) After deduction of applicable underwriters’ discounts, placement agent fees, and other offering costs.  Private Placement with Aspire Capital In July 2018, we entered into a securities purchase agreement (the “ PIPE Agreement ”) with Aspire Capital Fund LLC (“ Aspire Capital ”) for the sale of up to $2.0 million of shares of our common stock (or pre-funded warrants) and warrants, in two tranches. Upon the initial closing, we sold to Aspire Capital (i) a pre-funded warrant to purchase up to 2.5 million shares of our common stock with an exercise price of $0.01 per share (“ Pre-Funded Warrant ”) and (ii) a warrant to purchase up to 2.5 million shares of our common stock with an exercise price of $0.74 per share (a “ Warrant ”), for an aggregate purchase price of approximately $1.0 million. In addition, pursuant to the PIPE Agreement, in September 2018, we sold to Aspire Capital (i) a second Pre-Funded Warrant to purchase up to 2.5 million shares of common stock exercise price of $0.01 per share and (ii) a second Warrant to purchase an additional 2.5 million shares of common stock at an exercise price of $0.74 per share, for an additional aggregate purchase price of approximately $1.0 million. The aggregate proceeds from the sale of Pre-Funded Warrants and Warrants to Aspire Capital are $1.9 million after deduction of legal fees and registration costs of approximately $0.05 million. The Warrants and Pre-Funded Warrants expire five years after their respective issuance date and have substantially similar other terms, except (i) for exercise price and (ii) that the Warrants are exercisable on the date that is six months after issuance and the Pre-Funded Warrants are immediately exercisable after issuance. The shares underlying the Pre-Funded Warrants and Warrants are registered under a registration statement that became effective in September 2018 (Registration No.333-226738).  For the year ended December 31, 2019, we issued approximately 2.9 million shares of our common stock upon exercise of 2.9 million Pre-Funded Warrants and received proceeds totaling approximately $0.03 million. For the year ended December 31, 2018, we issued approximately 2.0 million shares of our common stock upon cashless exercise of 2.1 million Pre-Funded warrants. As of December 31, 2019, Aspire Capital had 5.0 million in outstanding warrants at an exercise price of $0.74 per share. In February 2020, we entered into a warrant amendment agreement with Aspire Capital whereby we repriced the outstanding warrants and issued new, replacement warrants (see Note 18).  Director Stock Purchases On March 26, 2018, three of our directors purchased an aggregate of 0.2 million shares of our common stock in an unregistered sale of equity securities at a purchase price of $0.83 per share. Director purchases of our common stock were made at or above market price at the date of purchase (see Note 16). At Market Issuance Sales Agreements In 2018, we completed the sale of approximately 1.4 million shares of our common stock at an average price of $0.87 per share under an At Market Issuance Sales Agreement (“ ATM ”) with FBR Capital Markets & Co. (“ FBR ”). The shares were registered under a November 2016 shelf registration statement (Registration No. 333-214598). We had no additional amounts available under the shelf registration statement as of December 31, 2018.  Equity Line Agreement In October 2017, we entered into a common stock purchase agreement (the “ Equity Line Agreement ”) with Aspire Capital. Under the Equity Line Agreement, Aspire Capital committed to purchase up to an aggregate of $20 million in shares of our common stock over the 30 -month term of the Equity Line Agreement. In consideration for entering into the Equity Line Agreement, we issued to Aspire Capital approximately 0.3 million shares of our common stock as a commitment fee. We filed a registration statement to register the sale of up to 4 million shares of our common stock by Aspire Capital under the Equity Line Agreement. The registration statement was declared effective November 27, 2017 (File No. 333-221250). As of December 31, 2018, we had issued all of the shares available under the registration statement. The term of the Equity Line Agreement expires in April 2020 and we do not anticipate registering any additional shares for sale under this agreement.  Stock and Warrant Issuances – Payment for Services Fisher Consulting In June 2019, we issued 625,000 shares of our common stock in exchange for a nonrefundable retainer for services under a consulting agreement with Mark Fisher, valued at approximately $60,000 . The value of the retainer was recognized as consulting expense over the six-month term of the agreement. The shares were registered on a registration statement that was declared effective on September 11, 2019 (File No. 333-233390).  Park Consulting In July 2019, we issued a warrant to purchase up to 1,800,000 shares of our common stock with an exercise price of $0.10 per share in exchange for a nonrefundable retainer for services under a consulting agreement with Park Consultants, LLC, valued at approximately $180,000 . The warrant is exercisable immediately after issuance and expires five years following the issuance date. The value of the warrant was determined using the Black-Scholes method. The value of the warrant is being recognized as consulting expense over the eighteen-month term of the consulting agreement. The shares underlying the warrant were registered on a registration statement that was declared effective on September 11, 2019 (File No. 333-233390).  Warrant Issuance in Connection with Debt Financing In December 2018, we issued a warrant for the purchase of up to 5.0 million shares of our common stock at $0.16 per share to Brickell in connection with an amendment to the CPIA (see Note 9). The CPIA is recorded as a liability at its estimated fair value. At the transaction date, the estimated fair value of the liability to Brickell exceeded the net proceeds received from Brickell. Accordingly, no value was assigned to the warrants issued in connection with the transaction. The warrant is immediately exercisable, expires five years from the date of issuance and includes cashless exercise and registration rights. The shares underlying the warrant were registered on a registration statement that was declared effective on April 19, 2019 (File No. 333-230888).  Common Stock Warrants As of December 31, 2019 and 2018, we had outstanding warrants for the purchase of up to 12.2 million shares and 13.3 million shares of our common stock, respectively. The estimated grant date fair value of these warrants of $1.3 million and $1.8 million at December 31, 2019 and 2018, respectively, is included in shareholders’ deficit in our consolidated balance sheets. As of December 31, 2019, our outstanding warrants have an average exercise price of $0.44 per share and a weighted average remaining life of approximately four years.  Shareholder Protection Rights Agreement On November 20, 2015, we amended our Shareholder Protection Rights Agreement (“ Rights Agreement ”) dated November 21, 2005. The amendment extends the expiration date of the Rights Agreement from November 21, 2015 to November 20, 2020 and decreases the exercise price of the rights to $14.50 after giving effect to the one -for-ten reverse stock split that became effective March 30, 2016.  The Rights Agreement provided for the issuance, on November 29, 2005, as a dividend, rights to acquire fractional shares of Series E Preferred Stock. We did not assign any value to the dividend as the value of these rights is not believed to be objectively determinable. The principal objective of the Rights Agreement is to cause someone interested in acquiring us to negotiate with our Board rather than launch an unsolicited or hostile bid. The Rights Agreement subjects a potential acquirer to substantial voting and economic dilution. Each share of common stock issued by ParkerVision will include an attached right.  The rights initially are not exercisable and trade with the common stock of ParkerVision. In the future, the rights may become exchangeable for shares of Series E Preferred Stock with various provisions that may discourage a takeover bid. Additionally, the rights have what are known as “flip-in” and “flip-over” provisions that could make any acquisition of us more costly to the potential acquirer. The rights may separate from the common stock following the acquisition of 15% or more of the outstanding shares of common stock by an acquiring person. Upon separation, the holder of the rights may exercise their right at an exercise price of $14.50 per right (the “ Exercise Price ”), subject to adjustment and payable in cash. Upon payment of the Exercise Price, the holder of the right will receive from us that number of shares of common stock having an aggregate market price equal to twice the Exercise Price, as adjusted. The Rights Agreement also has a flip over provision allowing the holder to purchase that number of shares of common/voting equity of a successor entity, if we are not the surviving corporation in a business combination, at an aggregate market price equal to twice the Exercise Price. We have the right to substitute for any of our shares of common stock that we are obligated to issue, shares of Series E Preferred Stock at a ratio of one ten-thousandth of a share of Series E Preferred Stock for each share of common stock. The Series E Preferred Stock, if and when issued, will have quarterly cumulative dividend rights payable when and as declared by the Board, liquidation, dissolution and winding up preferences, voting rights and will rank junior to other securities of ParkerVision unless otherwise determined by the Board. The rights may be redeemed upon approval of the Board at a redemption price of $0.01 . A s of December 31, 2019, there are no Series E preferred shares outstanding. 

Share-Based Compensation

Share-Based Compensation	12 Months Ended
	Dec. 31, 2019
Share-Based Compensation [Abstract]
Share-Based Compensation	14. SHARE-BASED COMPENSATION  The following table presents share-based compensation expense included in our consolidated statements of comprehensive loss for the years ended December 31, 2019 and 2018, respectively (in thousands):     2019 2018  Research and development expense $ 5 $ 169  Selling, general, and administrative expense 584 831  Restructuring expense - 50  Total share-based compensation expense $ 589 $ 1,050   We did not capitalize any expense related to share-based payments. As of December 31, 2019, there was $1.1 million of total unrecognized compensation cost related to all non-vested share-based compensation awards. That cost is expected to be recognized over a weighted-average period of approximately 1.4 years.  Stock Incentive Plans 2019 Long-Term Incentive Equity Plan We adopted a long-term incentive equity plan in August 2019 that provides for the grant of stock-based awards to employees, officers, directors and consultants, not to exceed 12.0 million shares of common stock (the “ 2019 Plan ”). The 2019 Plan provides for benefits in the form of nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 201 9 Plan become available for reissuance. The plan provides that no n-employee directors may not be granted awards that exceed the lesser of 1.0 million shares or $175,000 in value, calculated based on grant-date fair value .  On August 7, 2019, our Board approved the grant of nonqualified stock options for the purchase of an aggregate of 10,550,000 shares of our common stock with an exercise price of $0.17 per share, vesting in 8 equal quarterly increments commencing September 1, 2019. The option grants were made to executive officers, key employees and non-employee directors and have an aggregate grant date fair value of approximately $1.5 million. At December 31, 2019, 1,450,000 shares of common stock were available for future grants under the 2019 Plan.  2011 Long-Term Incentive Equity Plan We adopted a long-term incentive equity plan in September 2011 that, as amended in 2014, 2016 and 2017, provides for the grant of stock-based awards to employees, officers, directors and consultants, not to exceed 3.0 million shares of common stock (the “ 2011 Plan ”). The 2011 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 2011 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 150,000 shares in any calendar year. At December 31, 2019, 588,127 shares of common stock were available for future grants under the 2011 Plan.  2008 Equity Incentive Plan We adopted an equity incentive plan in August 2008 (the “ 2008 Plan ”). The 2008 Plan provides for the grant of stock-based awards to employees (excluding named executives), directors and consultants, not to exceed 50,000 shares of common stock. The 2008 Plan provides for benefits in the form of incentive stock options, nonqualified stock options, stock appreciation rights, restricted stock awards, and other stock based awards. Forfeited and expired options under the 2008 Plan become available for reissuance. The plan provides that no participant may be granted awards in excess of 5,000 shares in any calendar year. At December 31, 2019, 20,473 shares of common stock were available for future grants under the 2008 Plan.  2000 Performance Equity Plan We adopted a performance equity plan in July 2000 (the “ 2000 Plan ”). The 2000 Plan provided for the grant of options and other stock awards to employees, directors and consultants, not to exceed 500,000 shares of common stock. The 2000 Plan provided for benefits in the form of incentive and nonqualified stock options, stock appreciation rights, restricted stock awards, stock bonuses and various stock benefits or cash. No additional awards may be granted under this plan.  Restricted Stock Awards RSAs are issued as executive and employee incentive compensation and as payment for services to others. The value of the award is based on the closing price of our common stock on the date of grant. RSAs are generally immediately vested.  Restricted Stock Units RSUs are issued as incentive compensation to executives, employees, and non-employee directors. Each RSU represents a right to one share of our common stock, upon vesting. The RSUs are not entitled to voting rights or dividends, if any, until vested. RSUs generally vest over a one to three year period for employee awards and a one year period for non-employee director awards. The fair value of RSUs is generally based on the closing price of our common stock on the date of grant and is amortized to share-based compensation expense over the estimated life of the award, generally the vesting period .  RSAs and RSUs  The following table presents a summary of RSA and RSU activity under the 2000, 2008, 2011, and 2019 Plans (collectively, the “ Stock Plans ”) as of December 31, 2019 (shares in thousands):     Non-vested Shares  Shares Weighted-Average Grant Date Fair Value  Non-vested at beginning of year 14 $ 1.98  Granted - -  Vested (11) 1.98  Forfeited (3) 1.98  Non-vested at end of year - $ -   The total fair value of RSAs and RSUs vested under the Stock Plans for the year ended December 31, 2019 was $2,000 .  Stock Options Stock options are issued as incentive compensation to executives, employees and non-employee directors. Stock options are generally granted with exercise prices at or above fair market value of the underlying shares at the date of grant. The fair value of options granted is estimated using the Black-Scholes option pricing model. Generally, fair value is determined as of the grant date. Options for employees, including executives and non-employee directors, are generally granted under the Stock Plans.  The following table presents a summary of option activity under the Stock Plans for the year ended December 31, 2019 (shares in thousands):     Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value ($)  Outstanding at beginning of year 1,228 $ 7.09  Granted 10,550 0.17  Exercised - -  Forfeited (64) 0.63  Expired (304) 22.18  Outstanding at end of year 11,410 0.33 4.60 years $ -  Vested at end of year 3,435 $ 0.68 4.67 years $ -   The weighted average per share fair value of option shares granted during the years ended December 31, 2019 and 2018 was $0.14 and $0.46 , respectively. The total fair value of option shares vested was $0.5 million for each of the years ended December 31, 2019 and 2018.  The fair value of option grants under the Stock Plans for the years ended December 31, 2019 and 2018, respectively, was estimated using the Black-Scholes option-pricing model with the following assumptions:     Year ended December 31,  2019 2018  Expected option term 1 5 years 5 to 6 years  Expected volatility factor 2 119.1% 68.8% to 93.6%  Risk-free interest rate 3 1.6% 2.6% to 3.0%  Expected annual dividend yield 0% 0%  1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant. 3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.  Options by Price Range The options outstanding at December 31, 2019 under all plans have exercise price ranges, weighted average contractual lives, and weighted average exercise prices as follows (weighted average lives in years and shares in thousands):     Options Outstanding Options Vested  Range of Exercise Prices Number Outstanding at December 31, 2019 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2019 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life  $0.171 - $0.60 10,988 $ 0.19 4.62 3,013 $ 0.22 4.75  $1.98 - $13.80 411 2.81 4.24 411 2.81 4.24  $38.80 - $45.10 11 43.72 0.83 11 43.72 0.83  11,410 $ 0.33 4.60 3,435 $ 0.68 4.67   Upon exercise of options under all plans, we issue new shares of our common stock. For shares issued upon exercise of equity awards granted under the Stock Plans, the shares of common stock are registered. For shares issued upon exercise of non-plan awards, the shares are not registered unless they have been subsequently registered by us on a registration statement. We had no option exercises for the years ended December 31, 2019 or 2018 . 

Restructuring Charges

Restructuring Charges	12 Months Ended
	Dec. 31, 2019
Restructuring Charges [Abstract]
Restructuring Charges	15. RESTRUCTURING CHARGES  In August 2018, as a result of our limited capital resources, our Board approved plans to reduce our ongoing operating expenses, including a reduction in workforce of approximately 30 employees and closure of our engineering design facility in Lake Mary, Florida. As a result of the cost reduction measures, we ceased any ongoing integrated circuit design activities and significantly reduced our sales and marketing expenditures with respect to our Milo products. Expenses related to our restructuring are included in operating expenses in our consolidated statements of comprehensive loss under the heading “Restructuring charges.”  Restructuring charges for the year ended December 31, 2018 include the following (in thousands):     2018  One-time termination benefits $ 135  Lease expense 163  Asset impairment charges 375  Other 17  $ 690   Termination Benefits Accrued one-time termination benefits consist of the following (in thousands):     2018  Accrued termination benefits, beginning of period $ -  Termination benefits recognized 135  Termination benefits settled (115)  Accrued termination benefits, end of period $ 20   Lease Payable In connection with the cease-use date of our Lake Mary, Florida facility, we recorded a lease payable for the estimated fair value of remaining lease rental payments, less estimated sublease rentals, net of deferred rent. Our lease payable consists of the following (in thousands):     2018  Lease payable, beginning of period $ -  Present value of future minimum lease payments less estimated future sublease rentals, net of deferred rent of $62 182  Settlements (48)  Change in estimate 43  Lease payable, end of period 177  Current portion of lease payable 86  Long-term portion of lease payable $ 91   On January 1, 2019, we adopted ASC 842 (refer to Note 8, “Leases”) and recognized an operating lease liability of $0.52 million and a right-of-use asset of $0.34 million related to our Lake Mary facility .

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	16. RELATED PARTY TRANSACTIONS  We paid approximately $0.02 million and $0.03 million in 2019 and 2018, respectively, for patent-related legal services to SKGF, of which Robert Sterne, one of our directors since September 2006, is a partner. In addition, we paid approximately $0.06 million in 2018 for principal and interest on the SKGF Note (refer to “Note Payable to a Related Party” included Note 9) . No payments were made in 2019 on the SKGF Note. The SKGF Note has an outstanding balance, including accrued interest, of approximately $0.9 million at December 31, 2019 .  On September 10, 2018, we sold an aggregate of $0.4 million in promissory notes, convertible into shares of our common stock at a fixed conversion price of $0.40 to related parties on the same terms as other convertible notes sold in the same transaction (refer to “Convertible Notes” included in Note 9). Jeffrey Parker, our chief executive officer and chairman of the Board, and Paul Rosenbaum and Lewis Titt erton, two of our non-employee directors, each purchased a convertible note with a face value of $0.1 million. In addition, Stacie Wilf, sister to Jeffrey Parker , purchased a convertible note with a face value of $0.1 million.  On March 26, 2018, three of our directors purchased an aggregate of 0.2 million shares of our common stock in an unregistered sale of equity securities at a purchase price of $0.83 per share, which represented the closing bid price of our common stock on the purchase date. (see Note 13).

Concentrations Of Credit Risk

Concentrations Of Credit Risk	12 Months Ended
	Dec. 31, 2019
Concentrations Of Credit Risk [Abstract]
Concentration Of Credit Risk	17. CONCENTRATIONS OF CREDIT RISK  Financial instruments that potentially subject us to a concentration of credit risk principally consist of cash and cash equivalents. Cash and cash equivalents are primarily held in bank accounts and overnight investments. At times our cash balances on deposit with banks may exceed the balance insured by the F.D.I.C. 

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	18. SUBSEQUENT EVENTS  Debt and Equity Financings In January 2020, we sold an aggregate of $0.5 million in convertible notes to accredited investors. The notes mature five years from the date of issuance and are convertible, at the holders’ option, into shares of our common stock at a fixed conversion price of $0.13 per share. The notes bear interest at a stated rate of 8% per annum. Interest is payable quarterly, and we may elect, subject to certain equity conditions, to pay interest in cash, shares of our common stock, or a combination thereof. We also entered into a registration rights agreement with the investors pursuant to which we will register the shares underlying the notes. We have committed to file the registration statement by the 120th calendar day following the closing date and to cause the registration statement to become effective by the 180th calendar day following the closing date. The registration rights agreement provides for liquidated damages upon the occurrence of certain events including failure by us to file the registration statement or cause it to become effective by the deadlines set forth above. The amount of the liquidated damages is 1.0% of the aggregate subscription upon the occurrence of the event, and monthly thereafter, up to a maximum of 6% .  Also in January 2020, we received proceeds of approximately $0.2 million from the sale , on a private placement basis, of an aggregate of 1,169,232 shares of our common stock at a price of $0.13 per share, and 166,667 shares (together, the “Shares”) of our common stock at a price of $0.15 per share to accredited investors. The subscription agreements for the private placement transactions contain customary representations and warranties of the purchaser. We also entered into a registration rights agreement with the investors pursuant to which we will register the Shares. We have committed to file the registration statement by the 120th calendar day following the closing date and to cause the registration statement to become effective by the 180th calendar day following the closing date. The registration rights agreement provides for liquidated damages upon the occurrence of certain events including failure by us to file the registration statement or cause it to become effective by the deadlines set forth above. The amount of the liquidated damages is 1.0% of the aggregate subscription upon the occurrence of the event, and monthly thereafter, up to a maximum of 6% .  On February 28, 2020, we entered into a warrant amendment agreement (the “Warrant Amendment Agreement”) with Aspire Capital, with respect to warrants issued in July and September 2018 that are exercisable, collectively, into 5,000,000 shares of common stock (the “Existing Warrants”). The Warrant Amendment Agreement provides for a reduction in the exercise price for the Existing Warrants from $0.74 to $0.35 per share and the issuance of a new warrant for the purchase of 5,000,000 shares of common stock at an exercise price of $0.74 per share (the “New Warrant”). The Warrant Amendment Agreement also adds a call provision to the Existing Warrants whereby we may, after December 31, 2020, call for cancellation of all or a portion of the Existing Warrants in exchange for consideration of $0.001 per warrant share. The call provision is subject to certain conditions, including the continued existence of an effective registration statement for the underlying warrant shares and the availability of sufficient authorized shares to allow for the exercise of the Existing Warrant. In connection with the Warrant Amendment Agreement, Aspire Capital exercised a portion of the Existing Warrant for the purchase of approximately 1.5 million shares for net proceeds to us of approximately $0.5 million. We agreed to file a registration statement to register the shares underlying the New Warrant.  In March 2020, we received aggregate proceeds of $0.9 million from the sale , on a private placement basis, of an aggregate of 2,571,432 shares of our common stock at a price of $0.35 per share to accredited investors. The subscription agreements for the private placement transactions contain customary representations and warranties of the purchaser. We also entered into a registration rights agreement with the investors pursuant to which we will register the shares. We have committed to file the registration statement by the 60th calendar day following the closing date and to cause the registration statement to become effective by the 120th calendar day following the closing date. The registration rights agreement provides for liquidated damages upon the occurrence of certain events including failure by us to file the registration statement or cause it to become effective by the deadlines set forth above. The amount of the liquidated damages is 1.0% of the aggregate subscription upon the occurrence of the event, and monthly thereafter, up to a maximum of 6% .  The net proceeds of approximately $2.1 million from the 2020 debt and equity financings will be used to fund our operations, including litigation costs. Stock Issuance as Repayment of Outstanding Obligations On January 9, 2020, we issued 214,000 unregistered shares of our common stock as an in-kind payment of approximately $0.028 million in outstanding principal and accrued interest on a June 7, 2019 promissory note with an accredited investor (see “Unsecured Short-term Notes Payable in Note 9).  On January 15, 2020 we issued 500,000 unregistered shares of our common stock as an in-kind payment of approximately $0.075 million in outstanding amounts payable to Stacie Wilf, a related party.  On February 28, 2020, we issued an aggregate of 1,526,426 unregistered shares of our common stock as an in-kind payment of approximately $0.24 million in outstanding principal and accrued interest on a May 15, 2019 promissory note with an accredited investor . (see “Unsecured Short-term Notes Payable in Note 9).  Share Based Compensation Arrangements On January 14, 2020, the Board granted nonqualified stock options to purchase 218,000 shares at an exercise price of $0.21 and 171,000 RSAs to former directors in settlement of approximately $0.3 million in past Board and committee compensation fees. The options and RSAs vest immediately upon grant and the options expire five years from the grant date.  On February 9, 2020, the Board approved equity awards under the Company’s 2019 Long Term Incentive Plan (the “2019 Plan”) to executives as consideration for the executives’ voluntary reduction in base salaries since July 2018. The grants were made to the following individuals in the following amounts: RSUs for 300,000 shares to Jeffrey Parker, the Company’s Chief Executive Officer, RSUs for 150,000 shares to each of David Sorrells and Gregory Rawlins, the Company’s Chief Technical Officers, and an option to purchase 150,000 shares at an exercise price of $0.31 per share to Cynthia Poehlman, the Company’s Chief Financial Officer. Fifty percent ( 50% ) of the RSUs vest on May 9, 2020 and the remaining RSUs vest in four equal quarterly installments commencing August 9, 2020. The options vest 50% upon grant with the remainder vesting in four equal quarterly installments commencing May 10, 2020. In addition, on February 9, 2020, the Board approved equity awards to independent directors under the 2019 Plan for the directors’ continued waiver of all cash fees for board or committee service. The grants were made to the following directors in the following amounts: RSUs for 150,000 shares to Frank Newman and an option for the purchase of 150,000 shares at an exercise price of $0.31 per share to each of Robert Sterne and Paul Rosenbaum. The non-employee director awards all vest 50% upon grant with the remaining portion vesting in four equal quarterly installments commencing May 9, 2020. The Board also awarded an immediately vested option to purchase 100,000 shares at an exercise price of $0.31 per share under the Company’s 2011 Long Term Incentive Equity Plan to Robert Sterne in exchange for Mr. Sterne’s waiver of approximately $0.1 million in accrued and unpaid fees for board and committee service from 2016 to 2018. Each of the options awarded expire on February 9, 2027. 

Significant Accounting Polici_2

Significant Accounting Policies (Policy)	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation Our consolidated financial statements are prepared in accordance with generally accepted accounting principles in the U .S. (“ GAAP ”). Certain reclassifications have been made to prior period amounts to conform to the current period presentation. The consolidated financial statements include the accounts of ParkerVision, Inc. and our wholly-owned German subsidiary, ParkerVision GmbH, after elimination of all intercompany transactions and accounts.
Use of Estimates in the Preparation of Financial Statements	Use of Estimates in the Preparation of Financial Statements The preparation of financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. The more significant estimates made by us include projected future cash flows and risk-adjusted discount rates for estimating the fair value of our secured contingent payment obligation, the volatility and estimated lives of share-based awards used in the estimate of the fair market value of share-based compensation, the assessment of recoverability of long-lived assets, the amortization periods for intangible and long-lived assets, and the valuation allowance for deferred taxes. Actual results could differ from the estimates made. We periodically evaluate estimates used in the preparation of the financial statements for continued reasonableness. Appropriate adjustments, if any, to the estimates used are made prospectively based upon such periodic evaluation.
Cash and Cash Equivalents	 Cash and Cash Equivalents We consider cash and cash equivalents to include cash on hand, interest-bearing deposits, overnight repurchase agreements and investments with original maturities of three months or less when purchased.
Inventory	  Inventory Inventory is stated at the lower of actual cost, as determined under the first-in, first-out method, or estimated net realizable value. We review our inventory for estimated obsolescence or unmarketable inventory and write down inventory for the difference between cost and estimated market value based upon assumptions about future demand. Future demand is affected by market conditions, technological obsolescence, new products and strategic plans, each of which is subject to change. Due to the decision to discontinue Milo product sales in the fourth quarter of 2019, a full reserve was recorded against the remaining inventory on hand at December 31, 2019.
Property and Equipment	 Property and Equipment Property and equipment are stated at cost, less accumulated depreciation. Depreciation is determined using the straight-line method over the following estimated useful lives:     Manufacturing and office equipment 5 -7 years  Leasehold improvements Shorter of useful life or remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years  The cost and accumulated depreciation of assets sold or retired are removed from their respective accounts, and any resulting net gain or loss is recognized in the accompanying consolidated statements of comprehensive loss. The carrying value of long-lived assets is reviewed on a regular basis for the existence of facts, both internally and externally, that may suggest impairment. Recoverability of assets to be held and used is measured by comparing the carrying amount of an asset to the estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of the assets exceeds its estimated undiscounted future net cash flows, an impairment charge is recognized in the amount by which the carrying amount of the asset exceeds the fair value of the assets.
Intangible Assets	Intangible Assets Patents, copyrights and other intangible assets are amortized using the straight-line method over their estimated period of benefit. We estimate the economic lives of our patents and copyrights to be fifteen to twenty years. Management evaluates the recoverability of intangible assets periodically and takes into account events or circumstances that may warrant revised estimates of useful lives or that may indicate impairment exists.
Secured Contingent Payment Obligation	  Secured Contingent Payment Obligation We have accounted for our secured contingent repayment obligation as long-term debt in accordance with Accounting Standards Codification (“ ASC ”) 470-10-25, “Sales of Future Revenues or Various other Measures of Income.” Our repayment obligations are contingent upon the receipt of proceeds from patent enforcement and/or patent monetization actions. We have elected to measure our secured contingent payment obligation at its estimated fair value in accordance with ASC 825, “Financial Instruments” based on the variable and contingent nature of the repayment provisions. We have determined that the fair value of our secured contingent payment obligation falls within Level 3 in the fair value hierarchy which involves significant estimates and assumptions including projected future patent-related proceeds and the risk-adjusted rate for discounting future cash flows (see Note 10). Actual results could differ from the estimates made. Changes in fair value, including the component related to imputed interest, are included in the accompanying consolidated statements of comprehensive loss under the heading “Change in fair value of contingent payment obligation . ”
Leases	Leases In February 2016, the FASB established ASC 842, “Leases” by issuing Accounting Standards Update (“ ASU ”) 2016-02 to increase transparency and comparability among organizations by recognizing lease assets and lease liabilities on the balance sheet and disclosing key information about leasing arrangements. ASC 842 was subsequently amended by ASU 2018-01, ASU 2018-10 and ASU 2018-11 which provided practical expedients for adoption of ASC 842. Under the new guidance, a lessee will be required to recognize assets and liabilities for capital and operating leases with lease terms of more than 12 months. ASC 842 is effective for interim and annual periods beginning after December 15, 2018. A modified retrospective transition approach is required for adoption, applying the new standard to all leases existing at the date of initial application. An entity may choose to use either the effective date or the beginning of the earliest comparative period presented in the financial statements as its date of initial application.  We adopted ASC 842 as of January 1, 2019, and we have elected to use the effective date as the initial application date. Consequently, financial information will not be updated and the disclosures required under the new standard will not be provided for dates and period prior to January 1, 2019. The new standard provides a number of practical expedients in transition and we elected the package of practical expedients which permits us not to reassess under the new standard our prior conclusions about lease identification, lease classification and treatment of initial direct costs. The adoption of this new standard resulted in the recognition of operating lease right-of-use (“ ROU ”) assets and operating lease liabilities of approximately $0.56 million and $0.60 million, respectively, primarily related to our facilities leases.
Revenue Recognition	  Revenue Recognition As of January 1, 2018, we adopted ASC 606, “Revenue from Contracts with Customers” which implements a common revenue standard that clarifies the principles for recognizing revenue. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized. The adoption of ASC 606 had no material effect on our consolidated financial statements .  We derive revenue from licensing of our intellectual property, settlements from patent infringement disputes and sales of products. The timing of revenue recognition and the amount of revenue recognized depends upon a variety of factors, including the specific terms of each arrangement and the nature of our deliverables and obligations. In general, we recognize revenue when the performance obligations to our customers have been met. For the sale of products, the performance obligation is generally met at the time product is delivered to the customer. Estimated product returns are deducted from revenue and recorded as a liability. Revenue from the sale of our products includes shipping and handling charged to the customer. Product revenue is recorded net of sales tax collected from customers, discounts, and actual and estimated future returns.  The consideration received from patent license and settlement agreements is allocated to the various elements of the arrangement to the extent the revenue recognition differs between the elements of the arrangement. Elements related to past and future royalties as well as elements related to settlement will be recorded as revenue in our consolidated statements of comprehensive loss when our performance obligations related to each element have been met.
Shipping and Handling Costs	Shipping and Handling Costs Shipping and handling costs related to product sales for the years ended December 31, 2019 and 2018 were approximately $0.01 million each year. These costs are included in selling, general and administrative expenses in the accompanying consolidated statements of comprehensive loss.
Advertising Expense	Advertising Expense Advertising costs are expensed as incurred. Advertising expenses of approximately $0.04 million and $0.7 million for the years ended December 31, 2019 and 2018, respectively, are included in selling, general, and administrative expenses in the accompanying consolidated statements of comprehensive loss.
Research and Development Expenses	Research and Development Expenses Research and development costs are expensed as incurred and include salaries and benefits for employees engaged in research and development activities, costs paid to third party contractors, prototype expenses, an allocated portion of facilities costs, maintenance costs for software development tools, and depreciation.
Accounting for Share-Based Compensation	Accounting for Share-Based Compensation We have various share-based compensation programs which provide for equity awards including stock options, restricted stock units (“ RSUs ”) and restricted stock awards (“ RSAs ”). We calculate the fair value of employee share-based equity awards on the date of grant and recognize the calculated fair value as compensation expense over the requisite service periods of the related awards. We estimate the fair value of stock option awards using the Black-Scholes option valuation model. This valuation model requires the use of highly subjective assumptions and estimates including how long employees will retain their stock options before exercising them and the volatility of our common stock price over the expected life of the equity award. Such estimates, and the basis for our conclusions regarding such estimates, are outlined in detail in Note 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. We account for forfeitures of share-based awards as they occur.  As of January 1, 2018, we adopted ASU No. 2017-09, “Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting.” This update provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The adoption of this guidance did not have a material effect on our consolidated financial statements.  As of January 1, 2019, we adopted ASU 2018-07, "Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting." The amendments in this update simplify the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. We did not previously have awards to nonemployees that would require reassessment and therefore the adoption of ASU 2018-07 did not impact our consolidated financial statements.
Income Taxes	  Income Taxes The provision for income taxes is based on loss before taxes as reported in the accompanying consolidated statements of comprehensive loss. Deferred tax assets and liabilities are recognized for the expected future tax consequences of events that have been included in the financial statements or tax returns. Deferred tax assets and liabilities are determined based on differences between the financial statement carrying amounts and the tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established to reduce deferred tax assets when, based on available objective evidence, it is more likely than not that the benefit of such assets will not be realized. Our deferred tax assets exclude unrecognized tax benefits which do not meet a more-likely-than-not threshold for financial statement recognition for tax positions taken or expected to be taken in a tax return.  As of January 1, 2019, we adopted ASU 2018-02, “Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.” The amendments in this update allow a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act. We have no stranded tax effects included in our other comprehensive loss and therefore the adoption of ASU 2018-02 did not impact our consolidated financial statements.
Loss per Common Share	Loss per Common Share Basic loss per common share is determined based on the weighted-average number of common shares outstanding during each year. Diluted loss per common share is the same as basic loss per common share as all potential common shares are excluded from the calculation, as their effect is anti-dilutive.  The number of shares underlying outstanding options, warrants, unvested RSUs, and convertible notes at December 31, 2019 and 2018 were as follows (in thousands):     2019 2018  Options outstanding 11,410 1,228  Warrants outstanding 12,150 13,279  Unvested RSUs - 14  Shares underlying convertible notes 20,846 2,746  44,406 17,267   These potential shares were excluded from the computation of diluted loss per share as their effect would have been anti-dilutive.

Significant Accounting Polici_3

Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Significant Accounting Policies [Abstract]
Schedule Of Property And Equipment Useful Lives	   Manufacturing and office equipment 5 -7 years  Leasehold improvements Shorter of useful life or remaining life of lease  Furniture and fixtures 7 years  Computer equipment and software 3 -5 years 
Summary Of Anti-Dilutive Shares	   2019 2018  Options outstanding 11,410 1,228  Warrants outstanding 12,150 13,279  Unvested RSUs - 14  Shares underlying convertible notes 20,846 2,746  44,406 17,267  

Inventories (Tables)

Inventories (Tables)	12 Months Ended
	Dec. 31, 2019
Inventories [Abstract]
Schedule Of Inventories	   2019 2018  Raw materials $ - $ 139  Work-in-process - -  Finished goods 550 941  550 1,080  Inventory reserves (550) (982)  - 98  
Schedule Of Inventory Reserves	   2019 2018  Inventory reserves at beginning of year $ 982 $ -  Impairment charges 6 1,134  Write down of impaired inventories (438) (152)  Inventory reserves at end of year $ 550 $ 982  

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Prepaid Expenses [Abstract]
Schedule Of Prepaid Expenses	   2019 2018  Prepaid services $ 221 $ 252  Prepaid bonds for German statutory costs 188 199  Prepaid insurance 62 19  Prepaid licenses, software tools and support 17 51  Other prepaid expenses 17 17  $ 505 $ 538  

Property And Equipment, Net (Ta

Property And Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Property And Equipment, Net [Abstract]
Schedule Of Property And Equipment, Net	   2019 2018  Equipment and software, including equipment purchased under capital leases of $6 and $17 at December 31, 2019 and 2018, respectively $ 260 $ 1,555  Leasehold improvements 33 786  Furniture and fixtures 43 182  336 2,523  Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $3 and $13 at December 31, 2019 and 2018, respectively (266) (2,394)  $ 70 $ 129  

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2019
Intangible Assets [Abstract]
Schedule Of Intangible Assets	   2019 2018   Patents and copyrights $ 16,612 $ 18,350  Less accumulated amortization (13,734) (14,448)  $ 2,878 $ 3,902  
Schedule Of Future Amortization Expense	   2020 $ 473  2021 416  2022 373  2023 329  2024 303  2025 and thereafter 984  Total $ 2,878  

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2019
Accrued Liabilities [Abstract]
Other Accured Expenses	  2019 2018  Advances $ 500 $ -  Board compensation 413 413  Other accrued expenses 168 150  $ 1,081 $ 563  

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Leases [Abstract]
Supplemental Cash Flow Information	  Year Ended  December 31,  2019  Cash paid for amounts included in the measurement of lease liabilities:  Operating cash flows from operating leases $ 314  Operating cash flows from finance leases -  Financing cash flows from finance leases 1   Non-cash activity  Right-of-use assets obtained in exchange for operating lease liabilities 563  Assets obtained in exchange for finance lease liabilities -  
Supplemental Information	    December 31,  2019  Weighted-average remaining lease term (in years):  Operating leases 2.7  Finance leases 0.3  Weighted average discount rate  Operating leases (1) 12.0%  Finance leases 8.7%  Upon adoption of the new lease standard, discount rates used for existing leases were established at January 1, 2019.
Future Maturities of Lease Liabilities	   Operating Leases Finance Leases  2020 $ 295 $ 1  2021 176 -  2022 166 -  2023 4 -  Thereafter - -  Total undiscounted lease payments 641 1  Less: imputed interest (86) -  Present value of lease liabilities 555 1  Less: current obligations under leases (250) (1)  Long-term lease obligations $ 305 $ -  
Lease Commitments	   Description Lease Start Date Lease End Date Renewal options remaining Straight line monthly rental payment (in thousands)  Corporate office, Jacksonville, Florida 7/15/2018 7/31/2019 none $ 31  Wireless design facility, Lake Mary, Florida 7/1/2017 11/30/2022 2 options to extend for 36 months each $ 13  Warehouse and production facility, Jacksonville, Florida 7/1/2017 7/31/2020 none $ 2  
Contractual obligations	   Contractual obligations: 2019 2020 2021 and thereafter Total  Operating leases $ 372 $ 191 $ 345 $ 908  Capital leases $ 2 $ 1 $ - $ 3  

Long-Term Debt (Tables)

Long-Term Debt (Tables)	12 Months Ended
	Dec. 31, 2019
Long-Term Debt [Abstract]
Summary Of Aggregate Maturities	    2020 $ 1,533  2021 90  2022 703  Total $ 2,326  
Schedule Of Convertible Notes Payable	   Fixed Effective  Conversion Interest December 31,  Description Rate Rate Maturity Date 2019 2018  Convertible notes dated September 10, 2018 $0.40 8.3% September 7, 2023 $ 700 $ 800  Convertible notes dated September 19, 2018 $0.57 8.3% September 19, 2023 425 $ 425  Convertible notes dated February/March 2019 $0.25 8.0% February 28, 2024 to March 13, 2024 1,300 -  Convertible notes dated June/July 2019 $0.10 8.0% June 7, 2024 to July 15, 2024 390 -  Convertible notes dated July 18, 2019 $0.08 46.1% July 18, 2024 700 -  Convertible notes dated September 13, 2019 $0.10 25.9% September 13, 2024 50 -  Total principal balance 3,565 1,225  Less unamortized discount 832 388  $ 2,733 $ 837  
Reconciliation Of Secured Contingent Obligation At Fair Value	     2019 2018  Secured contingent payment obligation, beginning of year $ 25,557 $ 15,896  Proceeds from contingent payment obligation - 4,000  Change in fair value 1,094 5,661  Secured contingent payment obligation, end of year $ 26,651 $ 25,557  

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Fair Value Measurements [Abstract]
Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis	   Fair Value Measurements  Total Quoted Prices in Active Markets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3)  December 31, 2019:  Liabilities:  Secured contingent payment obligation $ 26,651 $ - $ - $ 26,651    December 31, 2018:  Liabilities:  Secured contingent payment obligation 25,557 - - 25,557  

Income Taxes And Tax Status (Ta

Income Taxes And Tax Status (Tables)	12 Months Ended
	Dec. 31, 2019
Income Taxes And Tax Status [Abstract]
Schedule Of Effective Income Tax Rate Reconciliation	   2019 2018  Tax benefit at statutory rate $ (1,985) $ (4,382)  State tax benefit (407) (897)  Increase in valuation allowance 2,341 5,304  Research and development credit - (51)  Other 51 26  $ - $ -  
Schedule Of Deferred Tax Assets And Liabilities	   2019 2018  Gross deferred tax assets:  Net operating loss carry-forward $ 83,865 $ 84,192  Research and development credit 7,608 7,879  Stock compensation (28) 1,027  Patents and other 1,479 1,495  Contingent payment obligation 3,119 2,842  Inventories 139 249  Fixed assets 2 25  Accrued liabilities 200 146  Deferred rent and lease liabilities 142 46  Charitable contributions 1 5  Capital loss carry-forward - 3  Warranty reserve 3 4  96,530 97,913  Less valuation allowance (96,320) (97,816)  210 97  Gross deferred tax liabilities:  Convertible debt (210) (97)  (210) (97)  Net deferred tax asset $ - $ -  
Schedule Of Unrecognized Tax Benefits Roll Forward	   2019 2018  Unrecognized tax benefits – beginning of year $ 927 $ 927  Unrecognized tax benefits – end of year $ 927 $ 927  

Stock Authorization And Issua_2

Stock Authorization And Issuance (Tables)	12 Months Ended
	Dec. 31, 2019
Stock Authorization And Issuance [Abstract]
Summary Of Equity Offerings	   Date Transaction # of Common Shares/ Units Sold Average Price per Share/Unit # of Warrants Issued (in 000’s) Average Exercise Price per Warrant Net Proceeds (1)  July 2018 and September 2018 Offerings under PIPE Agreement - - 10,000 $0.38 $ 1,901  March 2018 Director Stock Purchase 217 $0.83 - - $ 180  March - May 2018 Offerings under ATM 1,359 $0.87 - - $ 1,148  January - June 2018 Offerings under Equity Line Agreement 2,940 $0.70 - - $ 2,047  (1) After deduction of applicable underwriters’ discounts, placement agent fees, and other offering costs.

Share-Based Compensation (Table

Share-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule Of Share-Based Compensation Expense Included In Statements Of Operations	   2019 2018  Research and development expense $ 5 $ 169  Selling, general, and administrative expense 584 831  Restructuring expense - 50  Total share-based compensation expense $ 589 $ 1,050  
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Options Activity	   Shares Weighted- Average Exercise Price Weighted-Average Remaining Contractual Term Aggregate Intrinsic Value ($)  Outstanding at beginning of year 1,228 $ 7.09  Granted 10,550 0.17  Exercised - -  Forfeited (64) 0.63  Expired (304) 22.18  Outstanding at end of year 11,410 0.33 4.60 years $ -  Vested at end of year 3,435 $ 0.68 4.67 years $ -  
Summary Of Valuation Assumptions	   Year ended December 31,  2019 2018  Expected option term 1 5 years 5 to 6 years  Expected volatility factor 2 119.1% 68.8% to 93.6%  Risk-free interest rate 3 1.6% 2.6% to 3.0%  Expected annual dividend yield 0% 0%  1 The expected term was generally determined based on historical activity for grants with similar terms and for similar groups of employees and represents the period of time that options are expected to be outstanding. For employee options, groups of employees with similar historical exercise behavior are considered separately for valuation purposes. 2 The stock volatility for each grant is measured using the weighted average of historical daily price changes of our common stock over the most recent period equal to the expected option life of the grant. 3 The risk-free interest rate for periods equal to the expected term of the share option is based on the U.S. Treasury yield curve in effect at the measurement date.
Summary Of Options And Warrants By Exercise Price Range	   Options Outstanding Options Vested  Range of Exercise Prices Number Outstanding at December 31, 2019 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life Number Exercisable at December 31, 2019 Wtd. Avg. Exercise Price Wtd. Avg. Remaining Contractual Life  $0.171 - $0.60 10,988 $ 0.19 4.62 3,013 $ 0.22 4.75  $1.98 - $13.80 411 2.81 4.24 411 2.81 4.24  $38.80 - $45.10 11 43.72 0.83 11 43.72 0.83  11,410 $ 0.33 4.60 3,435 $ 0.68 4.67  
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Summary Of Restricted Stock Activity	   Non-vested Shares  Shares Weighted-Average Grant Date Fair Value  Non-vested at beginning of year 14 $ 1.98  Granted - -  Vested (11) 1.98  Forfeited (3) 1.98  Non-vested at end of year - $ -  

Restructuring Charges (Tables)

Restructuring Charges (Tables)	12 Months Ended
	Dec. 31, 2019
Restructuring Cost and Reserve [Line Items]
Schedule Of Restructuring Charges	   2018  One-time termination benefits $ 135  Lease expense 163  Asset impairment charges 375  Other 17  $ 690  
One-time Termination Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Schedule Of Accrued Reserve	   2018  Accrued termination benefits, beginning of period $ -  Termination benefits recognized 135  Termination benefits settled (115)  Accrued termination benefits, end of period $ 20  
Lease Payable [Member]
Restructuring Cost and Reserve [Line Items]
Schedule Of Accrued Reserve	   2018  Lease payable, beginning of period $ -  Present value of future minimum lease payments less estimated future sublease rentals, net of deferred rent of $62 182  Settlements (48)  Change in estimate 43  Lease payable, end of period 177  Current portion of lease payable 86  Long-term portion of lease payable $ 91  

Significant Accounting Polici_4

Significant Accounting Policies (Narrative) (Details) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2020USD ($)	Dec. 31, 2020USD ($)	Dec. 31, 2019USD ($)segment	Dec. 31, 2018USD ($)	Jan. 01, 2019USD ($)
Significant Accounting Policies [Line Items]
Operating segments | segment			1
Reportable segments | segment			1
Operating lease asset			$ 283		$ 340
Operating lease liability			86		$ 520
Shipping and handling costs			10	10
Advertising expenses			40	700
Proceeds from Issuance of Long-term Debt			3,068	$ 5,294
Accounting Standards Update 2016-02 [Member]
Significant Accounting Policies [Line Items]
Operating lease asset			560
Operating lease liability			$ 600
Scenario, Forecast [Member]
Significant Accounting Policies [Line Items]
Proceeds from debt and equity financings	$ 1,600	$ 2,100
proceeds from warrants	500
Proceeds from Issuance of Long-term Debt	600
Repayments of Long-term Debt, Long-term Capital Lease Obligations, and Capital Securities	$ 700
Patents And Copyrights [Member] | Minimum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life			15 years
Patents And Copyrights [Member] | Maximum [Member]
Significant Accounting Policies [Line Items]
Intangible assets, useful life			20 years

Significant Accounting Polici_5

Significant Accounting Policies (Schedule Of Property And Equipment Useful Lives) (Details)	12 Months Ended
	Dec. 31, 2019
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Useful life	Shorter of useful life or remaining life of lease
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Minimum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years
Minimum [Member] | Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	3 years
Maximum [Member] | Manufacturing And Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Useful life	7 years
Maximum [Member] | Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Useful life	5 years

Significant Accounting Polici_6

Significant Accounting Policies (Summary Of Anti-Dilutive Shares) (Details) - shares shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	44,406	17,267
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	11,410	1,228
Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	12,150	13,279
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares		14
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Shares	20,846	2,746

Liquidity And Going Concern (De

Liquidity And Going Concern (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Liquidity And Going Concern [Abstract]
Net loss	$ (9,453)	$ (20,869)
Net cash used in operating activities	(3,373)	(10,297)
Accumulated deficit	(401,783)	(392,292)
Net working capital	5,500
Net proceeds from debt financings	$ 3,068	$ 5,294

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Inventories [Abstract]
Raw materials		$ 139
Work-in-process
Finished goods	550	941
Inventory	550	1,080
Inventory reserves	(550)	(982)
Total inventories		$ 98

Inventories (Schedule Of Inve_2

Inventories (Schedule Of Inventory Reserves) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Inventories [Abstract]
Inventory reserves at beginning of year	$ 982
Impairment charges	6	1,134
Write down of impaired inventories	(438)	(152)
Inventory reserves at end of year	$ 550	$ 982

Prepaid Expenses (Narrative) (D

Prepaid Expenses (Narrative) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Prepaid Expenses [Abstract]
Impairment charges	$ 375

Prepaid Expenses (Schedule Of P

Prepaid Expenses (Schedule Of Prepaid Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Prepaid Expenses [Abstract]
Prepaid services	$ 221	$ 252
Prepaid bonds for German statutory costs	188	199
Prepaid licenses, software tools and support	17	51
Prepaid Insurance	62	19
Other prepaid expenses	17	17
Prepaid expenses	$ 505	$ 538

Property And Equipment, Net (Na

Property And Equipment, Net (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Assets held for sale		$ (70)
Gain (loss) on sale of assets held for sale and impairment	$ (40)	10
Corporate Headquarters [Member]
Property, Plant and Equipment [Line Items]
Gain (loss) on sale of assets held for sale	(10)	(10)
Property And Equipment [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	40	130
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Depreciation expense	$ 1	$ 2
Minimum [Member]
Property, Plant and Equipment [Line Items]
Capital lease term	1 year
Maximum [Member]
Property, Plant and Equipment [Line Items]
Capital lease term	3 years

Property And Equipment, Net (Sc

Property And Equipment, Net (Schedule Of Property And Equipment, Net) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Property and equipment	$ 336	$ 2,523
Less accumulated depreciation, including accumulated depreciation for equipment purchased under capital leases of $3 and $13 at December 31, 2019 and 2018, respectively	(266)	(2,394)
Property, Plant and Equipment, Net, Total	70	129
Capital leases	6	17
Accumulated depreciation for capital leases	3	13
Computer Equipment And Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	260	1,555
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	33	786
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 43	$ 182

Intangible Assets (Narrative) (

Intangible Assets (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Intangible Assets [Abstract]
Amortization expense	$ 0.6	$ 1.1
Loss on disposal	$ (0.4)	$ (0.1)

Intangible Assets (Schedule Of

Intangible Assets (Schedule Of Intangible Assets) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Intangible Assets [Abstract]
Patents and copyrights	$ 16,612	$ 18,350
Accumulated amortization	(13,734)	(14,448)
Intangible assets	$ 2,878	$ 3,902

Intangible Assets (Schedule O_2

Intangible Assets (Schedule Of Future Amortization Expense) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Intangible Assets [Abstract]
2020	$ 473
2021	416
2022	373
2023	329
2024	303
2025 and thereafter	984
Intangible assets	$ 2,878	$ 3,902

Accrued Liabilities (Narrative)

Accrued Liabilities (Narrative) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities [Abstract]
Board compensation	$ 413	$ 413
Aggregate grant-date fair value	$ 100

Accrued Liabilities (Other Accu

Accrued Liabilities (Other Accured Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Accrued Liabilities [Abstract]
Advances	$ 500
Board compensation	413	$ 413
Other accrued expenses	168	150
Accrued Liabilities	$ 1,081	$ 563

Leases (Narrative) (Details)

Leases (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019
Property Subject to or Available for Operating Lease [Line Items]
Operating lease cost	$ 400
Operating lease		$ 908
Rent expense		500
Lease liability	$ 86		$ 520
Wireless Design Facility [Member] | Lake Mary Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Operating lease		700
Lease liability		$ 200

Leases (Supplemental Cash Flow

Leases (Supplemental Cash Flow Information) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Leases [Abstract]
Operating cash flows from operating leases	$ 314
Operating cash flows from finance leases
Financing cash flows from finance leases	1
Right-of-use assets obtained in exchange for operating lease liabilities	563
Assets obtained in exchange for finance lease liabilities

Leases (Supplemental Informatio

Leases (Supplemental Information) (Details)	Dec. 31, 2019
Leases [Abstract]
Operating Lease, Weighted Average Remaining Lease Term	2 years 8 months 12 days
Finance Lease, Weighted Average Remaining Lease Term	3 months 18 days
Operating Lease, Weighted Average Discount Rate, Percent	12.00%
Finance Lease, Weighted Average Discount Rate, Percent	8.70%

Leases (Future Maturities of Le

Leases (Future Maturities of Lease Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Jan. 01, 2019	Dec. 31, 2018
Operating Lease Liabilities, Payments Due [Abstract]
2020	$ 295
2021	176
2022	166
2023	4
Total undiscounted lease payments	641
Less: imputed interest	(86)	$ (520)
Present value of lease liabilities	555
Less: current obligations under leases	(250)		$ (86)
Long-term lease obligations	305		$ 91
Finance Lease Liabilities, Payments, Due [Abstract]
2020	1
Total undiscounted lease payments	1
Present value of lease liabilities	1
Less: current obligations under leases	$ (1)

Leases (Lease Commitments) (Det

Leases (Lease Commitments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Subject to or Available for Operating Lease [Line Items]
Lease expense		$ 163
Corporate Office [Member] | Jacksonville Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 15, 2018
Lease End Date	Jul. 31, 2019
Lease expense	$ 31
Wireless Design Facility [Member] | Lake Mary Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 1, 2017
Lease End Date	Nov. 30, 2022
Renewal options remaining	36 months
Lease expense	$ 13
Warehouse And Production Facility [Member] | Jacksonville Florida [Member]
Property Subject to or Available for Operating Lease [Line Items]
Lease Start Date	Jul. 1, 2017
Lease End Date	Jul. 31, 2020
Lease expense	$ 2

Leases (Contractual obligations

Leases (Contractual obligations) (Details) $ in Thousands	Dec. 31, 2018USD ($)
Operating leases
2019	$ 372
2020	191
2021 and thereafter	345
Total	908
Capital leases
2019	2
2020	1
Total	$ 3

Long-Term Debt (Narrative) (Det

Long-Term Debt (Narrative) (Details)	1 Months Ended	2 Months Ended	3 Months Ended	12 Months Ended		36 Months Ended	48 Months Ended
	Jan. 31, 2020USD ($)$ / shares	Jun. 30, 2019USD ($)	Mar. 31, 2020USD ($)shares	Dec. 31, 2019USD ($)item$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2018USD ($)$ / sharesshares	Dec. 31, 2019USD ($)item$ / shares	Apr. 13, 2020USD ($)	Sep. 10, 2018USD ($)$ / shares
Debt Instrument [Line Items]
Proceeds from debt					$ 4,000,000
Fair value of note payable				$ 2,200,000			$ 2,200,000
Exercise price per warrant | $ / shares				$ 0.44			$ 0.44
Other liabilities				$ 400,000			$ 400,000
Accounts payable				2,328,000	$ 655,000	$ 655,000	2,328,000
Brickell [Member]
Debt Instrument [Line Items]
Shares converted, warrant | shares					5,000,000	5,000,000
Fair value of warrants					$ 0	$ 0
Exercise price per warrant | $ / shares					$ 0.16	$ 0.16
Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. [Member]
Debt Instrument [Line Items]
Accounts payable				1,600,000			1,600,000
Secured Debt [Member] | Brickell [Member]
Debt Instrument [Line Items]
Repayments of Debt							3,300,000
Proceeds from debt				0	$ 4,000,000	$ 18,000,000
Fair value of payment obligation					2,500,000	$ 2,500,000
Excess of fair value					800,000
Note Payable To A Related Party [Member] | Unsecured Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Debt Instrument [Line Items]
Debt				900,000			$ 900,000
Interest expense				$ 40,000	60,000
Note Payable To A Related Party [Member] | Secured Debt [Member] | Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. [Member]
Debt Instrument [Line Items]
Interest rate				12.00%			12.00%
Debt payment per month				$ 200,000
Debt, first payment date				Nov. 1, 2018
Installment payment				$ 100,000			$ 100,000
Repayments of Debt				1,200,000	100,000
Default interest				$ 20,000			$ 20,000
Transfer of capital stock				50.00%
Note Payable To A Related Party, Amendment A [Member] | Unsecured Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Debt Instrument [Line Items]
Interest rate				8.00%			8.00%
Debt payment per month				$ 48,500
Debt, first payment date				Oct. 31, 2018
Maturity date				Mar. 31, 2020
Note Payable To A Related Party, Amendment B [Member] | Unsecured Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Debt Instrument [Line Items]
Interest rate				4.00%			4.00%
Maturity date				Apr. 30, 2022
Note Payable To A Related Party, Amendment C [Member] | Unsecured Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Debt Instrument [Line Items]
Debt payment per month				$ 10,000
Balloon payment date				Apr. 1, 2022
Promissory Notes [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Interest rate				18.00%			18.00%
Proceeds from debt		$ 230,000
Interest expense				$ 30,000
Promissory Notes [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest rate				7.50%			7.50%
Proceeds from debt				$ 2,400,000	1,300,000
Beneficial conversion feature				600,000	400,000
Interest expense				320,000	50,000
Amortization				100,000	20,000
Contractual interest				$ 220,000	30,000
Amortization period				4 years 1 month 24 days
Outstanding principal converted				$ 100,000	$ 100,000
Shares issued | shares				250,000	250,000
Conversion price | $ / shares				$ 0.40	$ 0.40	$ 0.40	$ 0.40
Aggregate common stock | item				20,800,000
Contingent obligation, term				5 years
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Measurement input | item				0.25			0.25
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Two [Member]
Debt Instrument [Line Items]
Measurement input | item				0.20			0.20
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Three [Member]
Debt Instrument [Line Items]
Measurement input | item				0.15			0.15
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Prepayment Rate [Member] | Debt Instrument, Redemption, Period Four [Member]
Debt Instrument [Line Items]
Measurement input | item				0.10			0.10
Promissory Notes [Member] | Convertible Debt [Member] | Measurement Input, Default Rate [Member]
Debt Instrument [Line Items]
Measurement input | item				0.12			0.12
Promissory Notes [Member] | Convertible Debt [Member] | Related Parties [Member]
Debt Instrument [Line Items]
Debt									$ 400,000
Conversion price | $ / shares									$ 0.40
Modifed Promissory Notes [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Interest rate				20.00%			20.00%
Maturity date				Dec. 31, 2019
Other Notes [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest rate				8.00%			8.00%
Probability-Eeighted Income Approach [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Fair value of note payable				$ 26,700,000	$ 25,600,000	$ 25,600,000	$ 26,700,000
Subsequent Event [Member]
Debt Instrument [Line Items]
Proceeds from debt	$ 600,000
Upfront payment	$ 1,000,000
Termination payment								$ 5,000,000
Subsequent Event [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Interest rate	8.00%
Proceeds from debt	$ 500,000
Conversion price | $ / shares	$ 0.13
Contingent obligation, term	5 years
Subsequent Event [Member] | Note Payable To A Related Party [Member] | Secured Debt [Member] | Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. [Member]
Debt Instrument [Line Items]
Repayments of Debt			$ 1,200,000
Subsequent Event [Member] | Modifed Promissory Notes [Member] | Unsecured Note [Member]
Debt Instrument [Line Items]
Shares issued | shares			1,740,426
Minimum [Member] | Brickell [Member]
Debt Instrument [Line Items]
Percentage of proceeds payment				55.00%
Maximum [Member] | Brickell [Member]
Debt Instrument [Line Items]
Percentage of proceeds payment				100.00%

Long-Term Debt (Summary Of Aggr

Long-Term Debt (Summary Of Aggregate Maturities) (Details) $ in Thousands	Dec. 31, 2019USD ($)
Long-Term Debt [Abstract]
2020	$ 1,533
2021	90
2022	703
Convertible notes, net	$ 2,326

Long-Term Debt (Schedule Of Con

Long-Term Debt (Schedule Of Convertible Notes Payable) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt Instrument [Line Items]
Convertible notes, net	$ 2,733	$ 837
Convertible Debt [Member]
Debt Instrument [Line Items]
Total principal balance	3,565	1,225
Less Unamortized discount	832	388
Convertible notes, net	$ 2,733	837
Convertible Debt [Member] | Convertible Notes Dated September 10, 2018 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.40
Effective Interest Rate	8.30%
Maturity Date	Sep. 7, 2023
Total principal balance	$ 700	800
Convertible Debt [Member] | Convertible Note Dated September 19, 2018 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.57
Effective Interest Rate	8.30%
Maturity Date	Sep. 19, 2023
Total principal balance	$ 425	$ 425
Convertible Debt [Member] | Convertible Notes Dated February/March 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.25
Effective Interest Rate	8.00%
Total principal balance	$ 1,300
Convertible Debt [Member] | Convertible Note Dated June/July 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.10
Effective Interest Rate	8.00%
Total principal balance	$ 390
Convertible Debt [Member] | Convertible Note Dated July 18, 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.08
Effective Interest Rate	46.10%
Maturity Date	Jul. 18, 2024
Total principal balance	$ 700
Convertible Debt [Member] | Convertible Note Dated September 13, 2019 [Member]
Debt Instrument [Line Items]
Fixed Conversion Rate	$ 0.10
Effective Interest Rate	25.90%
Maturity Date	Sep. 13, 2024
Total principal balance	$ 50
Minimum [Member] | Convertible Debt [Member] | Convertible Notes Dated February/March 2019 [Member]
Debt Instrument [Line Items]
Maturity Date	Feb. 28, 2024
Minimum [Member] | Convertible Debt [Member] | Convertible Note Dated June/July 2019 [Member]
Debt Instrument [Line Items]
Maturity Date	Jun. 7, 2024
Maximum [Member] | Convertible Debt [Member] | Convertible Notes Dated February/March 2019 [Member]
Debt Instrument [Line Items]
Maturity Date	Mar. 13, 2024
Maximum [Member] | Convertible Debt [Member] | Convertible Note Dated June/July 2019 [Member]
Debt Instrument [Line Items]
Maturity Date	Jul. 15, 2024

Long-Term Debt (Reconciliation

Long-Term Debt (Reconciliation Of Secured Contingent Obligation At Fair Value) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Long-Term Debt [Abstract]
Secured contingent payment obligation, beginning of year	$ 25,557	$ 15,896
Proceeds from contingent payment obligation		4,000
Change in fair value	1,094	5,661
Secured contingent payment obligation, end of year	$ 26,651	$ 25,557

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details)	12 Months Ended
	Dec. 31, 2019USD ($)item	Dec. 31, 2018USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Assets level 1 to Level 2 transfers	$ 0	$ 0
Assets level 2 to Level 1 transfers	0	0
Liabilities level 1 to Level 2 transfers	0	0
Liabilities level 2 to Level 1 transfers	0	0
Change in fair value	1,094,000	5,661,000
Fair value of note payable	2,200,000
Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value	$ 3,900,000
Secured Debt [Member] | Measurement Input, Discount Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.165
Secured Debt [Member] | Measurement Input, Discount Rate [Member] | Result of a Decrease [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.08
Secured Debt [Member] | Measurement Input, Risk Free Interest Rate [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.025
Secured Debt [Member] | Measurement Input, Entity Credit Risk [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.08
Secured Debt [Member] | Measurement Input, Litigation Inherent Risk [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Measurement input | item	0.06
Secured Debt [Member] | Measurement Input, Expected Term [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Risk free term	2 years
Minimum [Member] | Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation	$ 0
Contingent obligation, probability	5.00%
Maximum [Member] | Secured Debt [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent obligation	$ 58,800,000
Contingent obligation, probability	25.00%
Probability-Eeighted Income Approach [Member] | Unsecured Note [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of note payable	$ 26,700,000	$ 25,600,000

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule Of Assets And Liabilities Measured At Fair Value On A Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member] - Secured Contingent Payment Obligation [Member] - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	$ 26,651	$ 25,557
Quoted Prices In Active Markets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Liabilities	$ 26,651	$ 25,557

Income Taxes And Tax Status (Na

Income Taxes And Tax Status (Narrative) (Details) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Tax Credit Carryforward [Line Items]
Foreign income tax expense
Current tax provision or benefit	$ 0	$ 0
Corporate tax rate	21.00%	21.00%
Operating loss carryforwards	$ 335,100,000
Operating loss carryforwards subject to expiration	314,800,000
Unrecognized tax benefits	927,000	$ 927,000	$ 927,000
Accrued interest or penalties	0	0
Income tax-related interest income, expense or penalties	0	$ 0
Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, Amount	$ 7,600,000
Minimum [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2020
Period subject to IRS examination	2000
Minimum [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2020
Maximum [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2037
Period subject to IRS examination	2019
Maximum [Member] | Research Tax Credit Carryforward [Member]
Tax Credit Carryforward [Line Items]
Operating loss carryforwards, expiration	Dec. 31, 2038
Convertible Debt [Member] | Promissory Notes [Member]
Tax Credit Carryforward [Line Items]
Unrecognized tax benefits	$ 200,000

Income Taxes And Tax Status (Sc

Income Taxes And Tax Status (Schedule of Effective Income Tax Rate Reconciliation) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Taxes And Tax Status [Abstract]
Tax benefit at statutory rate	$ (1,985)	$ (4,382)
State tax benefit	(407)	(897)
Increase in valuation allowance	2,341	5,304
Research and development credit		(51)
Other	51	26
Income Tax Expense (Benefit), Total

Income Taxes And Tax Status (_2

Income Taxes And Tax Status (Schedule of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Taxes And Tax Status [Abstract]
Net operating loss carry-forward	$ 83,865	$ 84,192
Research and development credit	7,608	7,879
Stock compensation	(28)	1,027
Patents and other	1,479	1,495
Contingent payment obligation	3,119	2,842
Inventories	139	249
Fixed assets	2	25
Accrued liabilities	200	146
Deferred rent and lease liabilities	142	46
Charitable contributions	1	5
Capital loss carry-forward		3
Warranty reserve	3	4
Deferred tax assets, gross	96,530	97,913
Less valuation allowance	(96,320)	(97,816)
Net deferred tax asset	210	97
Convertible debt	(210)	(97)
Deferred tax liabilities, gross	(210)	(97)
Net deferred tax asset

Income Taxes And Tax Status (_3

Income Taxes And Tax Status (Schedule of Unrecognized Tax Benefits Roll Forward) (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Income Taxes And Tax Status [Abstract]
Unrecognized tax benefits, beginning of year	$ 927	$ 927
Unrecognized tax benefits, end of year	$ 927	$ 927

Commitments And Contingencies (

Commitments And Contingencies (Details) $ in Thousands	1 Months Ended			12 Months Ended
	Mar. 31, 2017item	Dec. 31, 2015item	Aug. 31, 2015item	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Oct. 31, 2019USD ($)
Commitments and Contingencies [Line Items]
Rent expense | $					$ 500
Attorney fees | $				$ 413	413
Germany [Member]
Commitments and Contingencies [Line Items]
Statutory fees and costs | $				$ 370	$ 110
ParkerVision vs. Qualcomm, Inc. [Member]
Commitments and Contingencies [Line Items]
Number of petitions			10
Number of petitions outstanding	6
Number of patents allegedly infringed upon seeking invalidation			3
Number of patents allegedly infringed upon			11
Number of patents found infringed upon	3
Number of patents found not infringed upon	2
ParkerVision v. Apple and Qualcomm (Middle District of Florida) [Member]
Commitments and Contingencies [Line Items]
Number of additional patents allegedly infringed upon		4
ParkerVision v. Apple (Munich, Germany) Apple I Case [Member]
Commitments and Contingencies [Line Items]
Attorney fees | $						$ 60
Corporate Office [Member] | Jacksonville Florida [Member]
Commitments and Contingencies [Line Items]
Lease End Date				Jul. 31, 2019
Wireless Design Facility [Member] | Lake Mary Florida [Member]
Commitments and Contingencies [Line Items]
Lease End Date				Nov. 30, 2022
Warehouse And Production Facility [Member] | Jacksonville Florida [Member]
Commitments and Contingencies [Line Items]
Lease End Date				Jul. 31, 2020

Stock Authorization And Issua_3

Stock Authorization And Issuance (Narrative) (Details)

Mar. 26, 2018item$ / sharesshares

Oct. 17, 2017USD ($)shares

Mar. 30, 2016$ / shares

Jul. 31, 2019USD ($)$ / sharesshares

Jun. 30, 2019USD ($)shares

Sep. 30, 2018USD ($)$ / sharesshares

Jul. 31, 2018USD ($)$ / sharesitemshares

Mar. 31, 2016

Dec. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Nov. 30, 2019shares

Oct. 31, 2018shares

Jun. 12, 2018shares

Oct. 31, 2017shares

Nov. 17, 2005shares

Stock Authorization And Issuance [Line Items]

Preferred Stock, Shares authorized

15,000,000

100,000

Preferred Stock, Shares outstanding

0

Common stock, shares authorized

110,000,000

75,000,000

110,000,000

75,000,000

40,000,000

Exercise price per warrant | $ / shares

$ 0.44

Warrants | $

$ 1,330,000

$ 1,810,000

Sale of common stock, number of shares

1,800,000

2,900,000

Sale of common stock | $

$ 180,000

$ 5,276,000

Sale of stock price per share | $ / shares

$ 0.10

Shares of common stock issued upon exercise of warrants

12,200,000

13,300,000

Estimated fair market value | $

$ 1,300,000

$ 1,800,000

Issuance of stock to consultants, shares

625,000

Issuance of stocks to consultants | $

$ 60,000

Warrants, Options And Unvested RSUs [Member]

Stock Authorization And Issuance [Line Items]

Shares reserved for issuance

23,600,000

Pre-funded Warrant [Member]

Stock Authorization And Issuance [Line Items]

Sale of common stock, number of shares

30,000

2,100,000

Brickell [Member]

Stock Authorization And Issuance [Line Items]

Warrants to purchase common stock

5,000,000

Warrant term

5 years

Exercise price per warrant | $ / shares

$ 0.16

Aspire Capital [Member]

Stock Authorization And Issuance [Line Items]

Exercise price per warrant | $ / shares

$ 0.74

Warrants | $

$ 5,000,000

Series E Preferred Stock [Member]

Stock Authorization And Issuance [Line Items]

Preferred Stock, Shares outstanding

0

Common Stock [Member]

Stock Authorization And Issuance [Line Items]

Sale of common stock, number of shares

2,900,000

2,000,000

Sale of common stock | $

$ 45,000

Shareholder Approved Equity Compensation Plans [Member]

Stock Authorization And Issuance [Line Items]

Shares reserved for issuance

2,100,000

Market Issuance Sales Agreement [Member]

Stock Authorization And Issuance [Line Items]

Aggregate offering price | $

$ 0.87

Aggregate offering shares

1,400,000

Principal [Member] | Convertible Debt [Member]

Stock Authorization And Issuance [Line Items]

Shares reserved for issuance

20,800,000

Interest In-Kind [Member] | Convertible Debt [Member]

Stock Authorization And Issuance [Line Items]

Shares reserved for issuance

7,200,000

Offering Under PIPE Agreement [Member]

Stock Authorization And Issuance [Line Items]

Warrants to purchase common stock

1,900,000

2,000,000

Legal fees | $

$ 50,000

Warrant term

5 years

Number of tranches | item

2

Offering Under PIPE Agreement [Member] | Share-based Compensation Award, Tranche One [Member]

Stock Authorization And Issuance [Line Items]

Warrants to purchase common stock

2,500,000

2,500,000

Exercise price per warrant | $ / shares

$ 0.01

$ 0.01

Offering Under PIPE Agreement [Member] | Share-based Compensation Award, Tranche Two [Member]

Stock Authorization And Issuance [Line Items]

Aggregate offering price | $

$ 1,000,000

$ 1,000,000

Warrants to purchase common stock

2,500,000

2,500,000

Exercise price per warrant | $ / shares

$ 0.74

$ 0.74

Director Stock Purchase [Member] | Director [Member]

Stock Authorization And Issuance [Line Items]

Number of directors | item

3

Director Stock Purchase [Member] | Director [Member] | Common Stock [Member]

Stock Authorization And Issuance [Line Items]

Sale of common stock, number of shares

200,000

Sale of stock price per share | $ / shares

$ 0.83

Offerings under Equity Line Agreement [Member]

Stock Authorization And Issuance [Line Items]

Shelf, duration

30 months

Sale of common stock under commitment fee

0.3

Offerings under Equity Line Agreement [Member] | Maximum [Member]

Stock Authorization And Issuance [Line Items]

Aggregate offering price | $

$ 20,000,000

Aggregate offering shares

4,000,000

Rights Agreement [Member]

Stock Authorization And Issuance [Line Items]

Redemption price | $ / shares

$ 0.01

Exercise price per warrant | $ / shares

$ 14.50

Post reserve split ratio

0.1

Threshold percentage at which rights separte from common stock

15.00%

Stock Authorization And Issua_4

Stock Authorization And Issuance (Summary Of Equity Offerings) (Details) - USD ($) $ / shares in Units, shares in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2019	Dec. 31, 2018	Dec. 31, 2019
Equity Offerings [Line Items]
# of Common Shares/ Units Sold	$ 180,000	$ 5,276,000
Average Exercise Price Per Warrant			$ 0.44
Director Stock Purchase [Member] | March - May 2018 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 1,359,000
Average Price per Share/Unit		$ 0.87
Net Proceeds		$ 1,148,000
Offerings under ATM [Member] | March 2018 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 217,000
Average Price per Share/Unit		$ 0.83
Net Proceeds		$ 180,000
Offerings under ATM [Member] | January - June 2018 [Member]
Equity Offerings [Line Items]
# of Common Shares/ Units Sold		$ 2,940,000
Average Price per Share/Unit		$ 0.70
Net Proceeds		$ 2,047,000
Offerings under Equity Line Agreement [Member] | July 2018 and September 2018 [Member]
Equity Offerings [Line Items]
Number of warrants issued		10,000
Average Exercise Price Per Warrant		$ 0.38
Net Proceeds		$ 1,901,000

Share-Based Compensation (Narra

Share-Based Compensation (Narrative) (Details) - USD ($)	Aug. 07, 2019	Dec. 31, 2019	Dec. 31, 2018	Jan. 14, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost, net of estimated forfeitures		$ 1,100,000
Expected weighted average period to recognize the compensation cost, in years		1 year 4 months 24 days
2008 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant		20,473
Maximum number of shares per employee		5,000
Number of shares authorized		50,000
2000 Performance Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant		0
Number of shares authorized		500,000
2011 Long Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant		588,127
Maximum number of shares per employee		150,000
Number of shares authorized		3,000,000
2019 Long-Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares available for grant		1,450,000
Weighted average fair value of option shares granted	$ 1,500,000
Number of shares authorized	12,000,000
Restricted Stock Award And Restricted Stock Unit [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vested fair value		$ 2,000
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average fair value of option shares granted		$ 0.14	$ 0.46
Fair market value of vested shares		$ 500,000	$ 500,000
Intrinsic value of options exercised		$ 0	$ 0
Exercise price		$ 0.33
Nonqualified Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price				$ 0.21
Nonqualified Stock Options [Member] | 2019 Long-Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	10,550,000
Exercise price	$ 0.17
Minimum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year
Maximum [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		3 years
Non Employee Directors [Member] | Maximum [Member] | 2019 Long-Term Incentive Equity Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares per employee		1,000,000
Weighted average fair value of option shares granted		$ 175,000
Non Employee [Member] | Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period		1 year

Share-Based Compensation (Sched

Share-Based Compensation (Schedule Of Share-Based Compensation Expense Included In Statements Of Operations) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 589	$ 1,050
Research And Development Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	5	169
Selling, General and Administrative Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense	$ 584	831
Restructuring Expenses [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total share-based compensation expense		$ 50

Share-Based Compensation (Summa

Share-Based Compensation (Summary Of Restricted Stock Activity) (Details) - Restricted Stock Award And Restricted Stock Unit [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested at beginning of year, Shares | shares	14
Granted, Shares | shares
Vested, Shares | shares	(11)
Forfeited, Shares | shares	(3)
Non-vested at end of year, Shares | shares
Non-vested at beginning of year, Weighted-Average Grant-Date Fair Value | $ / shares	$ 1.98
Granted, Weighted Average Grant Date Fair Value | $ / shares
Vested, Weighted Average Grant Date Fair Value | $ / shares	1.98
Forfeited, Weighted Average Grant Date Fair Value | $ / shares	1.98
Non-vested at end of year, Weighted-Average Grant-Date Fair Value | $ / shares

Share-Based Compensation (Sum_2

Share-Based Compensation (Summary Of Option Activity) (Details) - Stock Options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding, Shares, Beginning of year | shares	1,228
Granted, Shares | shares	10,550
Exercised, Shares | shares
Forfeited, Shares | shares	(64)
Expired, Shares | shares	(304)
Outstanding, Shares, End of year | shares	11,410
Outstanding, Weighted Average Exercise Price, Beginning of year | $ / shares	$ 7.09
Granted, Weighted Average Exercise Price | $ / shares	0.17
Exercised, Weighted Average Exercise Price | $ / shares
Forfeited, Weighted Average Exercise Price | $ / shares	0.63
Expired, Weighted Average Exercise Price | $ / shares	22.18
Outstanding, Weighted Average Exercise Price, End of year | $ / shares	$ 0.33
Outstanding, Weighted Average Remaining Contractual Term	4 years 7 months 6 days
Outstanding, Aggregate Intrinsic Value | $
Vested and expected to vest at end of year, shares | shares	3,435
Vested and expected to vest at end of year, weighted average exercise price | $ / shares	$ 0.68
Vested and expected to vest at end of year, weighted average remaining contractual term	4 years 8 months 1 day
Vested and expected to vest at end of year, aggregate intrinsic value | $

Share-Based Compensation (Sum_3

Share-Based Compensation (Summary Of Valuation Assumptions) (Details) - Stock Options [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term	5 years
Expected volatility factor	119.10%
Risk-free interest rate	1.60%
Expected annual dividend yield	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term		5 years
Expected volatility factor		68.80%
Risk-free interest rate		2.60%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected option term	6 years
Expected volatility factor		93.60%
Risk-free interest rate		3.00%

Share-Based Compensation (Sum_4

Share-Based Compensation (Summary Of Options And Warrants By Exercise Price Range) (Details) - Stock Options [Member] shares in Thousands	12 Months Ended
	Dec. 31, 2019$ / sharesshares
Options Outstanding
Number Outstanding | shares	11,410
Wtd. Avg. Exercise Price	$ 0.33
Wtd. Avg. Remaining Contractual Life	4 years 7 months 6 days
Options Vested
Number Exercisable | shares	3,435
Wtd. Avg. Exercise Price	$ 0.68
Wtd. Avg. Remaining Contractual Life	4 years 8 months 1 day
$0.171 - $0.60 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 0.171
Exercise price maximum	$ 0.60
Options Outstanding
Number Outstanding | shares	10,988
Wtd. Avg. Exercise Price	$ 0.19
Wtd. Avg. Remaining Contractual Life	4 years 7 months 13 days
Options Vested
Number Exercisable | shares	3,013
Wtd. Avg. Exercise Price	$ 0.22
Wtd. Avg. Remaining Contractual Life	4 years 9 months
$1.98 - $13.80 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 1.98
Exercise price maximum	$ 13.80
Options Outstanding
Number Outstanding | shares	411
Wtd. Avg. Exercise Price	$ 2.81
Wtd. Avg. Remaining Contractual Life	4 years 2 months 27 days
Options Vested
Number Exercisable | shares	411
Wtd. Avg. Exercise Price	$ 2.81
Wtd. Avg. Remaining Contractual Life	4 years 2 months 27 days
$38.80 - $45.10 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Excercise price minimum	$ 38.80
Exercise price maximum	$ 45.10
Options Outstanding
Number Outstanding | shares	11
Wtd. Avg. Exercise Price	$ 43.72
Wtd. Avg. Remaining Contractual Life	9 months 29 days
Options Vested
Number Exercisable | shares	11
Wtd. Avg. Exercise Price	$ 43.72
Wtd. Avg. Remaining Contractual Life	9 months 29 days

Restructuring Charges (Narrativ

Restructuring Charges (Narrative) (Details) $ in Thousands	Dec. 31, 2019USD ($)	Jan. 01, 2019USD ($)	Dec. 31, 2018USD ($)	Aug. 31, 2018employee
Restructuring Cost and Reserve [Line Items]
Operating lease liability	$ 86	$ 520
Operating lease right of use assets	$ 283	$ 340
Lake Mary, Florida Facility [Member]
Restructuring Cost and Reserve [Line Items]
Employees | employee				30

Restructuring Charges (Schedule

Restructuring Charges (Schedule Of Restructuring Charges) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018USD ($)
Restructuring Charges [Abstract]
One-time termination benefits	$ 135
Lease expense	163
Asset impairment charges	375
Other	17
Restructuring charges	$ 690

Restructuring Charges (Schedu_2

Restructuring Charges (Schedule Of Accrued Reserve) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2018
Termination Benefits
Termination benefits recognized		$ 690
One-time Termination Benefits [Member]
Termination Benefits
Beginning of period	20
Termination benefits recognized		135
Termination benefits settled		(115)
End of period		20
Leases Payable
Beginning of period	20
Settlements		(115)
End of period		20
Long-Term Lease Payable
Lease payable	20	20	$ 20
Lease Payable [Member]
Termination Benefits
Beginning of period	177
Termination benefits settled		(48)
End of period		177
Leases Payable
Beginning of period	177
Present value of future minimum lease payments less estimated future sublease rentals, net of deferred rent of $62		182
Settlements		(48)
Change in estimate		43
End of period		177
Long-Term Lease Payable
Lease payable	$ 177	$ 177	177
Current portion of lease liability			86
Long-term portion of lease liability			91
Deferred rent			$ 62

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ / shares in Units, shares in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 31, 2020	Jul. 31, 2019	Sep. 10, 2018	Mar. 26, 2018
Related Party Transaction [Line Items]
Sale of stock price per share				$ 0.10
Common stock, shares issued	34,097	28,677
Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Related Party Transaction [Line Items]
Amount paid to related party	$ 20,000	$ 30,000
Three Directors [Member]
Related Party Transaction [Line Items]
Sale of stock price per share						$ 0.83
Common stock, shares issued						200
Convertible Debt [Member] | Subsequent Event [Member]
Related Party Transaction [Line Items]
Conversion price			$ 0.13
Interest rate			8.00%
Promissory Notes [Member] | Convertible Debt [Member]
Related Party Transaction [Line Items]
Conversion price	$ 0.40	$ 0.40
Interest rate	7.50%
Promissory Notes [Member] | Convertible Debt [Member] | Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Debt					$ 100,000
Promissory Notes [Member] | Convertible Debt [Member] | Stacie Wilf [Member]
Related Party Transaction [Line Items]
Debt					$ 100,000
Promissory Notes [Member] | Convertible Debt [Member] | Related Parties [Member]
Related Party Transaction [Line Items]
Conversion price					$ 0.40
Debt					$ 400,000
Promissory Notes [Member] | Convertible Debt [Member] | Mr. Paul Rosenbaum [Member]
Related Party Transaction [Line Items]
Debt					100,000
Promissory Notes [Member] | Convertible Debt [Member] | Lewis Titterton [Member]
Related Party Transaction [Line Items]
Debt					100,000
Promissory Notes [Member] | Convertible Debt [Member] | Two Non-Employee Directors [Member]
Related Party Transaction [Line Items]
Debt					$ 100,000
Promissory Notes [Member] | Unsecured Note [Member]
Related Party Transaction [Line Items]
Interest rate	18.00%
Promissory Notes [Member] | Unsecured Note [Member] | Sterne, Kessler, Goldstein & Fox, PLLC [Member]
Related Party Transaction [Line Items]
Amount paid to related party		$ 60,000
Secured notes payable	$ 900,000

Subsequent Events (Details)

Subsequent Events (Details) - USD ($)

Feb. 28, 2020

Feb. 09, 2020

Jan. 15, 2020

Jan. 14, 2020

Jan. 09, 2020

Mar. 31, 2020

Jan. 31, 2020

Jul. 31, 2019

Mar. 31, 2020

Dec. 31, 2020

Dec. 31, 2019

Dec. 31, 2018

Aug. 07, 2019

Subsequent Event [Line Items]

Proceeds from debt

$ 4,000,000

Sale of common stock, number of shares

1,800,000

2,900,000

Sale of common stock

$ 180,000

5,276,000

Sale of stock price per share

$ 0.10

Exercise price per warrant

$ 0.44

Compensation

$ 300,000

Accrued and unpaid fees

$ 413,000

$ 413,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Proceeds from debt

$ 600,000

Convertible Debt [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Proceeds from debt

$ 500,000

Term

5 years

Conversion price

$ 0.13

Interest rate

8.00%

Liquidated damages

1.00%

Maximum [Member] | Convertible Debt [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Liquidated damages

6.00%

Private Placement [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Liquidated damages

1.00%

1.00%

Sale of common stock, number of shares

2,571,432

1,169,232

Sale of common stock

$ 900,000

$ 200,000

Sale of stock price per share

$ 0.35

$ 0.13

$ 0.35

Private Placement [Member] | Maximum [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Liquidated damages

6.00%

6.00%

Private Placement, Accredited Investors [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Sale of common stock, number of shares

166,667

Sale of stock price per share

$ 0.15

Unregistered Shares [Member]

Subsequent Event [Line Items]

Sale of common stock, number of shares

1,526,426

500,000

214,000

Sale of common stock

$ 240,000

$ 75,000

$ 28,000

Warrant Amendment Agreement [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Warrants to purchase common stock

5,000,000

Exercise price per warrant

$ 0.35

Price per share of warrants expired

$ 0.001

Proceeds from warrants exercised

$ 1,500,000

Existing Warrants [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Warrants to purchase common stock

5,000,000

Exercise price per warrant

$ 0.74

Proceeds from warrants exercised

$ 500,000

Stock Options [Member]

Subsequent Event [Line Items]

Options granted

10,550,000

Exercise price

$ 0.33

Restricted Stock Award [Member]

Subsequent Event [Line Items]

Options granted

171,000

Nonqualified Stock Options [Member]

Subsequent Event [Line Items]

Options granted

218,000

Expiration period

5 years

Exercise price

$ 0.21

Robert Sterne [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Accrued and unpaid fees

$ 100,000

2019 Long-Term Incentive Equity Plan [Member] | Stock Options [Member] | Subsequent Event [Member] | Share-based Compensation Award, Tranche One [Member]

Subsequent Event [Line Items]

Vesting Percentage

50.00%

2019 Long-Term Incentive Equity Plan [Member] | Stock Options [Member] | Subsequent Event [Member] | Share-based Compensation Award, Tranche Two [Member]

Subsequent Event [Line Items]

Vesting Percentage

50.00%

2019 Long-Term Incentive Equity Plan [Member] | Nonqualified Stock Options [Member]

Subsequent Event [Line Items]

Exercise price

$ 0.17

2019 Long-Term Incentive Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member] | Share-based Compensation Award, Tranche One [Member]

Subsequent Event [Line Items]

Vesting Percentage

50.00%

2019 Long-Term Incentive Equity Plan [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member] | Share-based Compensation Award, Tranche Two [Member]

Subsequent Event [Line Items]

Vesting Percentage

50.00%

2019 Long-Term Incentive Equity Plan [Member] | Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Shares granted

300,000

2019 Long-Term Incentive Equity Plan [Member] | David Sorrells [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Shares granted

150,000

2019 Long-Term Incentive Equity Plan [Member] | Gregory Rawlins [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Shares granted

150,000

2019 Long-Term Incentive Equity Plan [Member] | Chief Financial Officer [Member] | Stock Options [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Options granted

150,000

Exercise price

$ 0.31

2019 Long-Term Incentive Equity Plan [Member] | Frank Newman [Member] | Restricted Stock Units (RSUs) [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Shares granted

150,000

2019 Long-Term Incentive Equity Plan [Member] | Robert Sterne [Member] | Stock Options [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Options granted

150,000

Exercise price

$ 0.31

2019 Long-Term Incentive Equity Plan [Member] | Paul Rosenbaum [Member] | Stock Options [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Options granted

150,000

Exercise price

$ 0.31

2019 Long-Term Incentive Equity Plan [Member] | Non Employee Directors [Member] | Stock Options [Member] | Subsequent Event [Member] | Share-based Compensation Award, Tranche One [Member]

Subsequent Event [Line Items]

Vesting Percentage

50.00%

2019 Long-Term Incentive Equity Plan [Member] | Non Employee Directors [Member] | Stock Options [Member] | Subsequent Event [Member] | Share-based Compensation Award, Tranche Two [Member]

Subsequent Event [Line Items]

Vesting Percentage

50.00%

Amended 2011 Long Term Incentive Equity Plan [Member] | Robert Sterne [Member] | Stock Options [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Options granted

100,000

Exercise price

$ 0.31

Scenario, Forecast [Member]

Subsequent Event [Line Items]

Proceeds from debt and equity financings

$ 1,600,000

$ 2,100,000